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The purpose of this dissertation is to define how the macrophage- 
stimulating protein (MSP) / Ron receptor tyrosine kinase pathway is involved in 
breast cancer-induced bone destruction and osteoclast activation. These studies 
employed in vitro osteoclast cultures and in vivo animal tumor models as 
systems to explore the ability of MSP to stimulate osteoclast activity and the 
ability of MSP-expressing tumor cells to cause bone destruction. I have also 
explored signaling downstream of Ron in osteoclasts and the requirement for 
Ron in bone destruction. I have utilized both genetic and pharmacological 
methods to target this pathway, thereby rigorously testing the ability of this 
pathway to activate osteoclasts. 
Included in the first part of this dissertation are two reviews. The first 
describes the MSP/Ron pathway, its function in cancer and inflammation, and the 
potential for targeting this pathway pharmacologically. The second review 
describes various mouse models used to study bone metastasis and bone 
destruction in vivo. 
The second part of this dissertation is focused on the ability of MSP/Ron 
to regulate osteoclast activation. Tumors overexpressing MSP spontaneously 
metastasize to bone and are osteolytic in an animal model of breast cancer. 




bone microenvironment, allowing for tumor growth and bone destruction. This 
study reveals the MSP/Ron pathway as a novel mediator of osteoclast activity, 
independent of previously established pathways such as RANKL and TGFβ. 
Additionally, I have demonstrated that the loss or inhibition of the MSP/Ron 
pathway can protect from bone loss due to both breast cancer and osteoporosis. 
This evidence establishes the importance of this pathway in osteoclast regulation 
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1.1 Bone remodeling 
The skeleton serves many functions, including structural support, 
maintenance of mineral homeostasis, as a reservoir of growth factors and 
cytokines, and it provides the environment for hematopoiesis within the marrow 
spaces (Taichman 2005). Bone is a highly dynamic organ that is continuously 
molded, shaped, and repaired. The microarchitecture of bone is developed to 
provide maximal strength with minimal mass according to the physiological 
needs of the organism. Once formed, bone undergoes a process termed 
remodeling that involves destruction (resorption) and building of new bone 
(synthesis), which occurs throughout the skeleton. In adults, approximately 10% 
of the skeleton is remodeled per year with the entire skeleton replaced every 10 
years. Remodeling is crucial to remove old, microdamaged bone and replace it 
with new, mechanically stronger bone to help preserve bone strength. The 
development and activation of osteoclasts is an essential process for skeletal 
growth during bone and mineral homeostasis. Homeostasis involves the removal 





mineralization of bone through the action of osteoblasts. Imbalances in 
remodeling can result in perturbations of skeletal structure and function. Many 
skeletal diseases are due to excess osteoclastic activity, leading to a net loss of 
bone mass and thereby increasing skeletal fragility and the risk of fracture. Such 
diseases include osteoporosis, osteolytic tumor metastases, rheumatoid arthritis, 
and multiple myeloma. 
 
1.2 Osteoclast function and lifecycle  
Osteoclasts are multinucleated cells derived from hematopoietic 
precursors of the monocyte-macrophage lineage. They are responsible for the 
degradation of mineralized bone matrix during organism development and 
growth, and for skeletal homeostasis, repair, and bone remodeling throughout life 
(Figure 1.1). Osteoclastic resorption is regulated by the rate of differentiation of 
osteoclasts from monocyte precursors, the activity level of mature osteoclasts, 
and the survival time of the mature cells (Baron 2011). The discovery of two key 
cytokines, sufficient to induce osteoclast differentiation, allowed a greater 
understanding of the regulation of osteoclastogenesis (Figure 1.2). Macrophage 
colony-stimulating factor (M-CSF) binds to its receptor c-Fms, leading to 
proliferation and survival of monocyte precursor cells. RANKL binds to its 
receptor RANK, and together with M-CSF initiates commitment and progression 
of early precursors to the osteoclast lineage (Asagiri 2007; Boyle 2003; Elford 
1987; Lacey 1998; Yoshida 1990). Upon commitment to the osteoclast lineage, 





cell fusion is a crucial component of osteoclastogenesis and is important for the 
cytoskeletal reorganization that is required for bone resorption. While the exact 
mechanisms regulating osteoclast precursor fusion remain largely unknown, one 
key factor involved is dendritic cell-specific transmembrane protein (DC-STAMP). 
Originally identified in dendritic cells, DC-STAMP is also expressed in 
macrophages and osteoclasts. A knockout animal model of DC-STAMP results in 
little to no fusion of osteoclasts, demonstrating the necessity of this factor in the 
fusion process (Yagi 2005). Other factors involved in the fusion process are 
Atp6v0d2, OC-STAMP, and CD9 (Ishii 2006; Lee 2006; Miyamoto 2012). 
Expression of these factors is largely dependent upon the key transcription 
factors NFATc1 and c-Fos, in conjunction with MITF and PU.1 (Mellis 2011). 
While several components involved in osteoclastogenesis have been identified, 
much work remains to delineate the processes involved and the interactions 
between key contributors in multinucleated osteoclast formation. 
There are many steps required for a mature osteoclast to actively resorb 
bone. Osteoclasts must first attach to the bone surface and migrate along the 
bone surface to the correct location. Next, they become polarized and form new 
specialized membrane domains. They then synthesize and secrete hydrolytic 
enzymes onto the bone matrix and acidify the resorption lacunae by using 
vacuolar proton pumps and chloride channels. Finally, they remove the 
extracellular bone matrix degradation products by internalization and 
transendocytosis of the matrix protein fragments (Baron 2011; Vaananen 2000). 





 1.2.1 Formation of the sealing zone 
After migration of the osteoclast to a resorption site, a specific membrane 
domain called the sealing zone or actin ring forms. The plasma membrane 
attaches tightly to the bone matrix and seals the resorption site from its 
surroundings, forming a resorption lacuna. This actin ring is composed of 
filamentous actin and densely packed podosomes, which consist of an actin core 
surrounded by cytoskeleton-regulating proteins such as vinculin, talin, paxilin, 
and cortactin (Zou 2010). While other molecules participate, the association of 
osteoclasts with bone matrix is primarily mediated by integrins. The αvβ3 integrin 
is highly expressed in osteoclasts and its cytoplasmic tail has been shown to 
recognize the RGD motif (Arg-Gly-Asp) contained in proteins residing within the 
bone matrix, such as osteopontin and bone sialic protein (Zou 2010). RGD-
containing protein engagement wtih αvβ3 leads to c-Src activation within the 
osteoclast cytoplasm. Syk is then recruited to the integrin-stimulated signaling 
complex by Dap12. Along with the adaptor protein Slp-76, Syk phosphorylates 
the guanine nucleotide exchange factor Vav3, which converts the Rho guanine 
trinucelotide phosphatase (GTPase) Rac from its inactive (GDP-bound) to its 
active (GTP-bound) form. Rac then reorganizes the osteoclast cytoskeleton, 
leading to actin ring formation (Izawa 2012). 
 
1.2.2 Bone resorption 
 Bone resorbing osteoclasts are highly polarized and contain distinct 





basolateral membrane. After the formation of the actin ring, osteoclasts form a 
specialized resorbing organelle, the ruffled border, within the actin ring structure. 
The ruffled border is formed by the fusion of intracellular acidic vesicles with the 
region of plasma membrane facing the bone matrix. The secretion of protease-
containing vesicles from the ruffled border onto the bone surface causes 
degradation of the collagen matrix and dissolution of hydroxyapatite mineral 
(Teitelbaum 2000). Several proteolytic enzymes are important for degrading the 
organic bone matrix, including lysosomal cysteine proteinases such as cathepsin 
K, and matrix metalloproteinases such as MMP9 and MMP13. In addition to 
degradation of the bone protein matrix, the dissolution of the crystalline 
hydroxyapatite within bone is achieved by targeted secretion of hydrochloric acid 
(HCl) into the resorption lacuna, through ATP-consuming vacuolar proton pumps. 
Protons for the proton pump are produced by cytoplasmic carbonic anhydrase II, 
while chloride channels in the ruffled border allow a flow of chloride anions into 
the resorption lacuna maintaining electroneutrality (Schlesinger 1997). After 
degradation, the byproducts are removed from the resorption lacuna through a 
transcytotic vesicular pathway from the ruffled border to the functional secretory 
domain where they are released into the extracellular space (Vaananen 2000). 
 
1.2.3 Osteoclast survival 
 In order to maintain the critical balance between bone resorption and bone 
formation, osteoclasts undergo apoptosis at sites where new bone is laid down 





estrogen is a key hormone that maintains bone mass, in part by promoting 
osteoclast apoptosis via regulating TGFβ and Fas ligand expression (Boyce 
2013). Osteoclast survival, on the other hand, is enhanced by various cytokines 
through up-regulation of Ras/Rac1/Erk and PI3K/mTOR/S6K signaling (Tanaka 
2006). Cytokine withdrawal leads to reduced expression of the anti-apoptotic 
protein, Bcl-2, and rapid apoptosis (Tanaka 2010). 
 
1.3 RANKL/RANK signaling in bone remodeling 
A breakthrough in the understanding of osteoclast differentiation and 
activation has come from the analysis of a family of biologically-related tumor 
necrosis factor (TNF) receptor/TNF-like proteins: osteoprotegerin (OPG), 
receptor activator of nuclear factor (NF)-kB (RANK), and RANK ligand (RANKL). 
These factors, along with M-CSF, are major players in the regulation of 
osteoclast function and survival. The RANKL polypeptide is a type II 
transmembrane protein found on the surface of expressing cells, but it also exists 
as a proteolytically released soluble form (Lacey 1998). Most hormones and 
factors that are known to stimulate bone resorption in vivo do so by inducing the 
expression of RANKL on stromal cells and osteoblasts. Activation of RANK on 
osteoclasts by RANKL leads to differentiation of osteoclast precursor cells, 
osteoclast activation, and survival. M-CSF, in conjunction with RANKL/RANK, is 
crucial for osteoclast differentiation and survival; one of the earliest effects of M-
CSF is to promote expression of RANK by myeloid progenitors, which primes the 





RANKL has been described as a key coupling factor linking osteoclast and 
osteoblast functions, contributing to the normally balanced activities of these two 
cell types. RANKL expression by osteoblasts coordinates bone remodeling by 
stimulating the differentiation and bone resorptive activity of local osteoclasts, 
which in turn stimulate bone synthesis by closely adjacent osteoblasts (Udagawa 
2000). While there are likely many coupling factors yet to be discovered, both 
semaphorins and ephrins have been implicated in the complex signaling between 
osteoblasts and osteoclasts, regulating their activity both positively and 
negatively (Sims 2014). However, there are other sources of RANKL aside from 
osteoblasts. During the process of bone formation, osteoblasts can become 
embedded within the bone matrix and differentiate into a specialized cell called 
the osteocyte. Osteocytes continue to live and function within the mineralized 
tissue by forming long dendrite-like extensions that are important for signaling 
and the exchange of nutrients and waste throughout the canaliculi and with cells 
in the marrow cavity. Moreover, osteocytes are thought to be mechanosensor 
cells that control the activity of osteoblasts and osteoclasts by influencing the 
balance of activity in these cell types depending on the mechanical loading of the 
bone (Xiong 2012). For example, osteocytes specifically express Sclerostin, 
which inhibits osteoblasts by antagonizing Wnt signaling, but also produce 
RANKL, resulting in increased osteoclastogenesis (Komori 2013). While their role 
in bone remodeling has historically been underappreciated, recent work has shed 
light on the crucial functions osteocytes play in the regulation of bone biology. 





osteoblasts are not essential osteoclast support cells: ablation of osteoblasts had 
no effect on osteoclast surface or bone resorption markers and did not affect the 
basal RANKL mRNA levels in the bone (Corral 1998, Galli 2009). These results 
were surprising; the accepted model had been that osteoblasts were essential for 
regulating osteoclast function and did so through the production of RANKL. 
Osteocytes were also known to produce RANKL, but it was not thought that they 
produce levels that are high enough to significantly affect osteoclast activity. 
Definitive proof for the osteocyte as a crucial regulator of osteoclast function 
came from experiments performed using osteocyte-specific conditional deletion 
of RANKL in mice. Deletion of RANKL in osteocytes resulted in reduction of 
osteoclast numbers and markers of bone resorption, and an increase in bone 
mass with age. Importantly, the lack of RANKL in osteocytes had no effect on 
bone resorption during development, suggesting that osteocyte-derived RANKL 
specifically contributes to bone remodeling in adults (Nakashima 2011; Xiong 
2011). These results strongly suggested that osteocytes, not osteoblasts, are an 
essential source of RANKL controlling osteoclast formation during cancellous 
bone remodeling. Regardless of the source, these experiments clearly 
established the importance of RANKL in regulating the function of osteoclasts. 
OPG was originally discovered as a soluble protein produced by 
osteoblasts that could block osteoclast formation in vitro and bone resorption in 
vivo. Later, OPG was discovered to function as a decoy receptor that can block 
binding of RANKL to its cellular receptor, RANK. Expression of RANKL and OPG 





positively and negatively by controlling the activation state of RANK on 
osteoclasts (Boyle 2003). 
Activation of RANK by its ligand leads to expression of osteoclast-specific 
genes during differentiation, activation, and during survival. At least five distinct 
signaling cascades mediated by protein kinases are induced during 
osteoclastogenesis and activation: inhibitor of NF-kB kinase (IKK), c-Jun N-
terminal kinase (JNK), p38 MAPK, extracellular signal-regulated kinase (ERK), 
and Src pathways. Like other TNF receptor family members, RANK lacks intrinsic 
kinase activity to phosphorylate and activate downstream signaling molecules. 
TNFR-associated cytoplasmic factor 6 (TRAF6) acts as a key adaptor allowing 
RANK to assemble signaling proteins that direct osteoclast-specific gene 
expression. For example, stimulation of p38 results in the downstream activation 
of the transcriptional regulator Mitf, which controls the expression of the genes 
encoding tartrate-resistant acid phosphatase (TRAP) and cathepsin K. Mitf, 
cathepsin K, and TRAP are all required by the mature osteoclast for bone 
resorption (Mansky 2002). RANK- and M-CSF-mediated signaling through PI3K 
and the serine/threonine protein kinase Akt act in cooperation with Src to induce 
cell survival, cytoskeletal rearrangements, and motility (Wong 1999). Finally, 
RANKL signaling through NF-kB p65 prevents Bid- and Caspase3-induced 
osteoclast apoptosis (Vaira 2008), while M-CSF prevents apoptosis by several 
mechanisms, including activation of Bcl-2 via Mitf, increased degradation of Bim 
by c-Cbl, and upregulation of Bcl-XL (Tanaka 2006; Tanaka 2010). The discovery 





of osteoclast function and its role in bone biology. In addition to these 
discoveries, however, RANKL-induced differentiation of osteoclasts has served 
as a useful tool for the discovery of a network of numerous other pathways 
regulating osteoclast function. 
 
 
1.4 RANKL-independent mechanisms of bone remodeling 
Despite the importance of M-CSF and RANKL in osteoclast function, 
several factors have been identified that can substitute for either of these factors 
under certain conditions or in specific osteoclast processes. The importance of 
M-CSF in osteoclast formation is evidenced by the fact that op/op osteopetrotic 
mice, which exhibit a spontaneous mutation in the M-CSF encoding gene (Csf1), 
have very few osteoclasts and markedly decreased bone resorption (Felix 1990; 
Yoshida 1990). However, the presence of some osteoclasts and the fact that 
op/op mice undergo a spontaneous age-dependent recovery of 
osteoclastogenesis suggested that there may be factors that can substitute for 
M-CSF function (Begg 1993; Felix 1994). Indeed, in vitro studies have 
demonstrated that there are several growth factors capable of regulating 
osteoclast function, at least to a certain degree, in the absence of M-CSF. Both 
Flt3 ligand and vascular endothelial growth factor (VEGF) have been shown to 
support osteoclastogenesis in the absence of functional M-CSF. Osteoclasts that 
formed upon addition of Flt3 or VEGF are multinucleated, express TRAP, and 
are capable of lacunar resorption. However, they were significantly smaller in 





osteoclasts (Lean 2001;Niida 1999). Addition of hepatocyte growth factor (HGF) 
in lieu of M-CSF also results in differentiation and activation of osteoclasts in vitro 
(Adamopoulos 2006). Similar to that of Flt3 and VEGF stimulated osteoclasts, 
the HGF-stimulated osteoclasts are smaller compared to M-CSF-stimulated cells 
but were actually capable of significantly greater resorption than Flt3- or VEGF-
stimulated cells. Similar results were also demonstrated with placental growth 
factor (PlGF), suggesting functional redundancy between several growth factors 
that are highly expressed in the bone marrow environment (Taylor 2012). The 
addition of these growth factors to osteoclasts stimulated with M-CSF and 
RANKL also results in significant increases in differentiation and activation, 
suggesting that growth factors may modulate these functions with the majority of 
regulation controlled by M-CSF. In addition, these growth factors may provide a 
salvage pathway for osteoclast formation in the absence of M-CSF, though the 
role these factors play under in vivo physiologic conditions has yet to be 
demonstrated (Taylor 2012). 
In addition to potential M-CSF-independent osteoclastogenesis 
mechanisms, several RANKL-independent mechanisms have also been 
discovered. Interleukin-6 (IL-6), interleukin-11 (IL-11), and tumor necrosis factor 
α (TNF-α) have all been shown to increase proliferation and differentiation of 
osteoclast precursor cells in vitro, independent of RANKL. These factors are also 
capable of stimulating a limited amount of resorption and, in the case of IL-1, are 
capable of prolonging osteoclast survival in the absence of RANKL (Fuller 2002; 





functions under normal conditions in vivo is unclear, there is evidence for an 
important role for several of these cytokines in bone loss associated with 
pathologic diseases. For example, TNFα is crucial in the pathogenesis of bone 
and joint destruction that occurs in rheumatoid arthritis and other forms of chronic 
inflammatory osteolysis (Fuller 2002). It has also been reported that TNFα, IL-6, 
and IL-11 mediate bone loss associated with estrogen deficiency (Kimble 1996; 
Cenci 2000; Jilka 1992; Manolagas 1995). Finally, IL-6 has been implicated in 
the pathogenesis of osteolysis associated with Paget’s disease, multiple 
myeloma, and Gorham-Stout disease (Kudo 2003). It is not clear, however, 
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Adapted from Zhenya Senyak, MPNforum.com 
 
Figure 1.2 The lifecycle of an osteoclast. Maturation occurs on bone from 
peripheral blood-born mononuclear cells with traits of the macrophage lineage. 
M-CSF (CSF-1) and RANKL are essential for osteoclastogenesis and throughout 
the lifespan of an osteoclast. Exposure of mononuclear cells to M-CSF leads to 
proliferation and expression of the RANK receptor. RANKL, produced by 
osteoblasts and osteocytes, leads to cell-fate commitment and the expression of 
proteins responsible for fusion. Mononuclear osteoclast precursor cells then fuse, 
forming a multinuclear osteoclast containing approximately 10 to 20 nuclei. 
Further stimulation by M-CSF and RANKL leads to the expression of proteins 
required for the reorganization of the cytoskeleton, adhesion, and formation of 
the sealing zone. The fully mature, activated osteoclast then begins to produce 
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MSP/RON IS A NOVEL MEDIATOR OF OSTEOCLAST ACTIVATION 
 THAT PROMOTES BREAST CANCER-INDUCED BONE 
 DESTRUCTION AND OSTEOPOROSIS 
 
 













Despite evidence supporting an oncogenic and bone metastatic role in 
breast cancer, the role of the Ron receptor tyrosine kinase pathway in the bone 
microenvironment during metastasis remains unknown. Here, I report that the 
Ron ligand, macrophage-stimulating protein (MSP), is an important contributor to 
cancer-meditated osteolysis. MSP overexpression leads to a significant increase 
in the ability of tumor cells to destroy bone and this ability requires Ron activity in 
host osteoclasts. MSP-driven osteoclast activation does not require RANKL or 
TGFβ signaling and, importantly, pharmacological inhibition of Ron can prevent 
both the development of osteolysis and the progression of existing osteolysis. In 
addition, I demonstrate that the MSP/Ron pathway is pertinent to other cases of 
pathogenic osteoclast activation; this pathway also functions in bone loss due to 
osteoporosis. These findings elucidate an important role for the MSP/Ron 
pathway in osteoclast activation, providing rationale for the use of Ron inhibitors 




 MSP promotes osteolytic bone destruction 
 Activation of osteoclasts by MSP/Ron does not depend on RANKL or 
TGFβ signaling 
 Lack of Ron tyrosine kinase prevents osteoporosis-mediated bone loss 






My study reveals a new mechanism by which osteoclasts become 
activated in vivo. Activation of Ron tyrosine kinase leads to osteoclast activity 
and bone resorption through a mechanism that is not dependent on RANKL, 
which is widely recognized as a key regulator of pathogenic osteoclast activity. I 
have also discovered a role for the MSP/Ron pathway in osteoporosis-related 
bone loss, suggesting that the pathogenic effects of MSP/Ron signaling in bone 
are not limited to cancer. Importantly, pharmacological inhibition of Ron reduced 
both MSP-mediated tumor osteolysis and osteoporotic bone loss, providing 
preclinical support for the use of Ron inhibitors as therapeutic agents against 
pathological bone loss. 
 
4.4 Introduction 
Macrophage-stimulating protein (MSP, also known as human MST1 or 
mouse HGFL; hepatocyte growth factor like) is a plasminogen-related growth 
factor that was originally identified as a serum protein that caused macrophage 
chemotaxis and activation. MSP is secreted as an inactive single-chain precursor 
(pro-MSP), which becomes active after proteolytic cleavage, forming a disulfide-
linked heterodimer (Danilkovitch and Leonard 1999). The first protease identified 
to activate pro-MSP under biological conditions was membrane-type serine 
protease 1 (MT-SP1, also known as ST14 or matriptase) (Bhatt 2007). However, 
it is now apparent that there are other proteases capable of pro-MSP maturation 





growth factor activator (HGFA) (Ganesan 2011; Kawaguchi 2009; Orikawa 
2012). MSP exerts several important biological effects depending on the cell type 
in which its receptor, macrophage-stimulating-1 receptor (MST1R, or Ron), 
becomes activated. MSP is the only known ligand for Ron, and Ron is one of 
only two members of a distinct receptor tyrosine kinase family that also includes 
Met (Wang 1995). Ron is expressed in many tissues during development; 
however, in adults its expression is restricted to certain epithelial-derived cells 
(such as keratinocytes), nociceptive neurons, resident tissue macrophages, and 
osteoclasts. MSP can promote migration and survival of epithelial cell lines and 
can promote an epithelial-to-mesenchymal transition in immortalized canine 
kidney cells in vitro (Cote 2007; Pagan 1999; Wang 1996).  
In addition to the effects the MSP/Ron pathway has in a normal cellular 
context, evidence now suggests an important role in the cancer setting. Ron is 
expressed at high levels in many different epithelial cancers as well as 
malignancies of brain and bone (Kretschmann 2010). MSP and Ron are 
coordinately overexpressed in over 20% of human breast cancers, and their 
overexpression along with matriptase has been shown to be an independent 
prognostic indicator for metastasis and poor survival (Welm 2007). 
Overexpression of Ron in breast epithelial cells leads to the transformation of cell 
lines and metastatic tumor development in mice (Feres 2009; Zinser; 2006). 
Overexpression of MSP in tumor cells driven by the polyomavirus middle T 
antigen under the control of the mouse mammary tumor virus promoter (MMTV-





metastasis to other organs (Welm 2007). The fact that MSP was sufficient to 
promote spontaneous metastasis to bone is noteworthy, as spontaneous bone 
metastasis has proven very difficult to achieve in genetically engineered mouse 
models. The bone metastases that developed in this model were osteolytic, 
replicating what is most commonly seen in human breast cancer patients. 
Interestingly, the overexpression of Ron in mammary tumors did not lead to an 
increase in bone metastasis (Zinser 2006; A.L.W. unpublished data), suggesting 
a non-cell autonomous mechanism where tumor-host interactions may play a key 
role in MSP-driven bone metastasis. 
Over 70% of patients with metastatic breast cancer have bone 
metastases. These metastases cause a number of complications, including 
severe pain, nerve compression, hypercalcemia, and debilitating bone fractures 
(Colman 2002; Deil 2000). The development and growth of bone metastases 
depend on the interactions between tumor cells and cells within the bone 
microenvironment. Bone homeostasis is normally maintained by balanced 
osteoclast and osteoblast activities, and it is the ability of tumor cells to disrupt 
this delicate balance that results in bone destruction and metastatic tumor 
growth. The “vicious cycle” hypothesis describes the complex interactions that 
result in bone destruction and subsequent metastatic tumor growth:  As active 
osteoclasts resorb bone, growth factors such as TGFβ are released from the 
bone matrix into the bone-tumor microenvironment. Such growth factors not only 
increase survival and proliferation of the metastatic tumor cells, but also lead to 





interleukin 11. These proteins indirectly lead to further osteoclast differentiation 
and activation by stimulating secretion of receptor activator of nuclear factor-kB 
ligand (RANKL) from osteoblasts. RANKL is a key mediator of 
osteoclastogenesis and osteoclast activity, thus completing the cycle of bone 
resorption and metastatic tumor growth (Guise and Mundy 1998; Weilbaecher 
2011). 
Ron is expressed in osteoclasts and expression of Ron increases 
dramatically during osteoclast differentiation (Yang 2008). In addition, MSP has 
been shown to cause activation, but not differentiation, of osteoclasts in vitro 
(Kurihara 1996; Kurihara 1998). This suggests that the ability of MSP to drive 
osteolytic bone metastasis (Welm 2007) may be due to a favorable interaction of 
MSP with differentiated, mature osteoclasts, but such a role has never been 
elucidated in vivo. Although several molecular contributors of bone metastasis 
have been identified, of which RANKL is key, identification of other targetable 




4.5.1 Ron expression in the host is required for MSP-driven  
breast cancer osteolysis 
We have previously shown that MSP drives spontaneous osteolytic bone 
metastasis (Welm 2007). To investigate the hypothesis that MSP-mediated bone 





PyMT or PyMT-MSP tumor cells (Welm 2007) into the tibias of wild-type (WT) 
mice or mice in which the tyrosine kinase domain of Ron has been deleted from 
the genome (RonTK -/-) (Waltz 2001). Expression of MSP in the tumor cells 
significantly increased the ability of these tumors to induce osteolysis in WT 
bones (Figure 4.1A). In contrast, when tumors overexpressing MSP were 
injected into RonTK-/- bones, they induced very little osteolysis. This was 
comparable to the basal levels of osteolysis induced in control tumor cells 
(Figures 4.1A and 4.1B). MSP-driven osteolysis could not be explained by 
altered tumor growth in the bone, as no statistically significant differences in 
tumor size or proliferation were observed between cohorts (Figures 4.1C and 
4.1D). Thus, Ron activity in the host was required for the ability of MSP- 
expressing tumor cells to induce osteolysis in the bone microenvironment. The 
presence of residual tumor-induced osteolysis caused by control tumors both in 
WT and RonTK -/- mice demonstrates some degree of osteolysis that is 
independent of the MSP/Ron pathway, likely RANKL-mediated (addressed 
below).  
To determine if MSP-driven osteolysis was due to an increase in the 
number of osteoclasts present within the microenvironment, bone sections were 
stained for the osteoclast-specific protein tartrate resistant acid phosphatase 
(TRAP) and the number of TRAP-positive (TRAP+) multinuclear cells were 
quantified. We detected no significant difference in the number of TRAP+ 
osteoclasts when comparing bones harboring control tumors versus MSP 





tumor-bearing bones to determine whether the RonTK-/- mice displayed a defect 
in osteoclastogenesis. Again, there was no difference in the number of 
osteoclasts present in the bones of RonTK -/- mice when compared to WT mice 
(Figures 4.1E and 4.S1A). 
To determine if protection from osteolysis in the Ron TK-/- mice was due 
to an increase in bone formation due to elevated osteoblast activity, WT and Ron 
TK-/- bones were labeled in vivo and histomorphometric bone parameters were 
analyzed. There were no significant differences in the mineral apposition rate 
(MAR) or the bone formation rate (BFR), indicating that there is no inherent 
difference in osteoblast activity between WT and Ron TK-/- mice (Figures 4.S1B-
D). To ensure that a tyrosine kinase-independent function of Ron was not 
contributing to osteoblast activity, we also examined bones of mice completely 
lacking murine Ron (STK) protein (Correll 1997).  Again, no differences in 
osteoblast activity were seen between WT and total Ron knockout mice (STK-/-) 
(Figures 4.S1B, 4.S1E-F). Consistent with this finding, staining bone sections 
with antibodies specific for Ron showed expression in osteoclasts and 
chondrocytes, but not in osteoblasts (Figure 4.S1G), and no Ron or 
phosphorylated Ron expression was detected in the MC3T3-E1 osteoblast cell 
line (Figure 4.S1H). Together, these data strongly suggest that the ability of 
MSP-expressing tumor cells to induce osteolysis was not due to changes in 
osteoclast numbers or osteoblast activity. We therefore pursued the hypothesis 






4.5.2 Host Ron activity drives osteolysis from metastatic  
human breast cancer 
To ensure that our findings were not restricted to the effects of mouse 
tumors or tumors engineered to overexpress MSP, we examined the expression 
levels of MSP, Ron, and matriptase in a panel of human breast cancer cell lines 
and chose a cell line (DU4475), which expressed each of these genes above an 
average expression level, similar to our previous report on patient tumor samples 
(Figure 4.S2A; Welm 2007). The metastatic breast cancer cell line DU4475 was 
selected and injected into the tibias of WT or RonTK-/- mice (both crossed with 
NOD.SCID and then backcrossed into the FVB genetic background). While the 
DU4475 cell line was osteolytic in NOD.SCID mice carrying wild-type alleles of 
Ron (NOD.SCID/RonTK+/+), osteolysis was significantly reduced in the 
NOD.SCID/RonTK-/- mice (Figures 4.2A and 4.2B). These results show that 
MSP/Ron-dependent osteolysis is not restricted to the mouse overexpression 
model, but can be expanded to include human cell lines that naturally 
overexpress endogenous MSP. Again, there was no significant difference in the 
number of TRAP+ osteoclasts in NOD.SCID/RonTK+/+ versus 
NOD.SCID/RonTK-/- mice harboring DU4475 tumors (Figures 4.2C and 4.2D) or 
in normal, non-tumor-bearing NOD.SCID/RonTK+/+ and NOD.SCID/RonTK-/- 
mice (Figures 4.S2B and 4.S2C). Again, the lack of osteolysis could not be 







4.5.3 T cells are dispensable for MSP-induced osteolysis 
Because the above xenograft experiments had to be performed in 
immune-compromised mice, and because T cells have previously been shown to 
influence osteoclast activity (Takayanagi 2012), we wanted to ensure that the 
lack of tumor-induced osteolysis from human DU4475 cells in 
NOD.SCID/RonTK-/- mice was not due to a combination effect of Ron TK 
deletion and the compromised immune system. To test whether T cells were 
required for MSP/Ron-dependent osteolysis, we compared the effects of injecting 
PyMT-MSP tumor cells into the tibias of syngenic immune-competent 
(FVB/RonTK+/+ or FVB/RonTK-/-), or immune-compromised 
(NOD.SCID/RonTK+/+ or NOD.SCID/RonTK-/-) mice. MSP-mediated osteolysis 
was not significantly altered in the immune-compromised mice and still 
demonstrated the necessity for Ron activity in the host (Figures 4.S2D and 
4.S2E). There was also no significant difference in tumor growth or in the number 
of TRAP+ osteoclasts in these experiments (Figures 4.S2F-H). While not 
statistically significant, there was a trend toward increased growth in the immune-
deficient background, but no difference in osteolysis. These data show that the 
mechanism for MSP-driven bone destruction does not require T-cell activity, or 
any other component of the adaptive immune system. 
 
 4.5.4 Treatment with Ron inhibitors blocks osteolysis 
Based on the data obtained using RonTK-/- mice, we tested whether 





injected tibias with MSP-expressing PyMT tumor cells or DU4475 breast cancer 
cells and treated them with two different small molecule tyrosine kinase inhibitors 
that are selective for Ron and Met (OSI-296 and ASLAN002). OSI-296 is more 
selective for Met (IC50 of 42 nM for Met and 200 nM for Ron; Steinig 2013), while 
ASLAN002 (also known as BMS-777607) is more selective for Ron (IC50 of 3.9 
nM for Met and 1.8 nM for Ron; Schroeder 2009). When animals were treated 
with either drug, beginning 3 days after tumor injection, osteolysis from PyMT-
MSP tumors was significantly inhibited, phenocopying the results obtained with 
RonTK-/- mice. OSI-296 caused an average 4-6 fold inhibition of osteolysis and 
ASLAN002 caused 6-10 fold inhibition of osteolysis (Figures 4.3A-D). 
ASLAN002, but not OSI-296, also prevented osteolysis from DU4475 cells 
(Figures 4.3E and 4.3F). Ron inhibition did not have an effect on the ability of 
tumors that do not express MSP to cause osteolysis, again implicating an 
osteolytic pathway that is independent of MSP/Ron signaling (Figures 4.S3A and 
4.S3B). To determine the potential of Ron inhibitors in a more clinically relevant 
setting, we allowed the animals to develop osteolysis that was visible by X-ray in 
live animals, and then began treatment (this was, on average, 3 weeks after 
tumor injection). While the osteolysis in vehicle treated mice continued to 
progress, Ron inhibition was able to prevent further tumor-induced bone loss. 
These results carry clinical relevance, as they suggest that Ron inhibitors could 
be useful in the postmetastatic, post-osteolytic setting (Figures 4.3A and 4.3C). 
Treatment with OSI-296 also reduced PyMT-MSP tumor growth and proliferation 





growth, but did not reach statistical significance (Figures 4.S3D-F). Neither drug 
significantly inhibited growth of DU4475 tumors (Figure 4.S3G). Again, Ron 
inhibition had no significant effect on the number of TRAP+ osteoclasts present 
(Figures 4.S4A and 4.S4B). Ron inhibitors also did not affect RANKL production 
as measured by serum ELISA, suggesting that the lack of bone destruction was 
not due to indirect inhibition of RANKL signaling (Figure 4.3G). Ron inhibitors 
also did not affect bone formation in vivo, supporting a model in which blockade 
of Ron signaling leads to a specific reduction in osteoclast activity, not an 
increase in osteoblast activity (Figures 4.S4C-S4E). 
 
4.5.5 MSP/Ron signaling is a novel mechanism of osteolysis  
that is not dependent on RANKL or TGFβ signaling 
Both RANKL and TGFβ have been shown to play major roles in osteoclast 
activation and the “vicious cycle.” Denosumab, a RANKL antagonist, was 
recently FDA-approved to treat bone metastases and osteoporosis based on 
demonstration of increased time to development of skeletal-related events, such 
as fracture, in patients (Cummings 2009; Papapoulos 2012; Stopeck 2010). 
Mechanistically, we wanted to determine if MSP/Ron functionally interacts with 
RANKL and/or TGFβ pathways. To test whether MSP-driven osteolysis is 
dependent on activation of RANK by RANKL, we treated mice with the murine 
RANKL antagonist, muRANK-Fc, 3 days after intratibial injection of tumor cells. 
As expected based on existing literature (Canon 2008; Holland 2010), 





treatment with the RANKL antagonist (Figures 4.4A and 4.4B), despite no 
significant effect on tumor growth (Figure 4.S5A). These data support the 
observation that the low level of Ron-independent osteolysis present in control 
tumors is dependent upon the RANKL pathway and, importantly, that the 
antagonist is functional in our assays. However, PyMT tumor cells 
overexpressing MSP were able to cause significant osteolysis even in the 
presence of the RANKL antagonist. In addition, although the levels of MSP-
driven osteolysis in the Ron TK-/- mice were already very low, inhibition of 
RANKL did not reduce this further (Figures 4.4A and 4.4B). Staining of sections 
from these samples demonstrated successful RANKL inhibition by the lack of 
TRAP+ cells in these groups, as expected from published literature 
demonstrating that TRAP expression is regulated downstream of RANK (Canon 
et al., 2008) (Figure 4.4C). However, osteoclasts were still present following 
RANKL inhibition, as demonstrated by NFATc1 and Ron immuno-staining (Figure 
4.S5C). These data suggest that although the RANKL antagonist is effective in 
our assays, the ability of MSP to induce osteolysis does not require active 
RANKL signaling. 
The TGFβ pathway has also been shown to be an integral part of the 
“vicious cycle.” TGFβ is released from the bone matrix by osteoclasts and binds 
to its receptor on tumor cells, stimulating production of pro-osteoclastogenic 
cytokines. Mechanisms of osteolysis involving TGFβ that are potentially RANKL-
independent have been suggested (Itonaga 2004; Sethi 2011); therefore, it is 





osteoclast activation. To test this possibility, we utilized PyMT tumor cells in 
which the TGFβ type-II receptor (TGFβRII) had been deleted using a Cre-lox 
system (Forrester 2005). We then overexpressed MSP and injected these cells 
into WT mice. While the absence of TGFβ signaling did not affect tumor growth 
(Figure 4.S5D), it did affect the ability of control tumors to induce basal levels of 
osteolysis (Figures 4.4D and 4.4E). Similar to RANKL inhibition, TGFβRII loss in 
the tumor cells impaired the ability of control tumors to induce osteolysis. This 
again supports the notion that the basal level of osteolysis induced by PyMT 
control tumor cells is dependent on RANKL and TGFβ signaling. Tumors 
overexpressing MSP, in contrast, caused robust osteolysis regardless of whether 
they expressed TGFβRII. Taken together, this evidence suggests that, while the 
RANKL-TGFβ portion of the vicious cycle is active in the PyMT model of bone 
metastasis, MSP/Ron activates osteoclasts through a mechanism that does not 
depend on RANKL or TGFβ. 
To further test the hypothesis that MSP/Ron is sufficient to stimulate 
osteolysis in a manner that does not rely on the RANKL pathway, we utilized 
another human breast cancer model (MDA-MB-231), which has been previously 
shown to be highly dependent on RANKL for osteolysis (Canon 2008). 
Concordant with this, MDA-MB-231 cells do not express MSP at detectable 
levels (Figure 4.5A), allowing us to assess the consequences of MSP 
overexpression, which occurs in approximately 40% of human breast cancers 
(Welm et al., 2007). We overexpressed MSP in this cell line and injected these 





significant increase in the ability of these cells to induce osteolysis (Figures 4.5B 
and 4.5C). While treatment with the RANKL antagonist again reduced osteolysis 
from control tumor cells, it did not significantly reduce the osteolysis from MSP-
expressing tumor cells. Treatment with OSI-296, in contrast, was able to reduce 
MSP-mediated osteolysis to levels seen in control tumor cells. These data 
demonstrate that MSP gain-of-function can significantly increase osteolysis 
through a mechanism that can override RANKL dependency. Taken together, our 
data strongly suggest that the MSP/Ron pathway is a novel mediator of 
osteoclast activity in bone-metastatic breast cancer. 
 
4.5.6 MSP/Ron signaling promotes bone degradation by  
stimulating RANK-independent osteoclast survival, c-Src  
phosphorylation, and osteolytic activity 
To determine the cellular mechanism by which Ron signaling functions in 
specific steps during osteoclastogenesis and osteoclast activation, we analyzed 
the effect of MSP on osteoclasts in vitro. Differentiated osteoclasts were 
stimulated with recombinant MSP, and their ability to resorb an artificial bone 
matrix was analyzed. Addition of MSP to WT osteoclasts led to a significant 
increase in the resorptive capacity of these cells, while having no effect on 
RonTK-/- osteoclasts (Figures 4.6A and 4.S6A). This increase in osteoclast 
resorption was only slightly reduced upon addition of the RANKL antagonist 
(Figure 4.6B), but was dramatically reduced upon addition of Ron inhibitors 





the RANKL antagonist and either of the Ron inhibitors reduced osteoclast activity 
to a greater extent than either treatment alone (Figures 4.6C and 4.S6B), again 
suggesting that both Ron and RANKL contribute to bone destruction, but do so 
through separate pathways in osteoclast activation. 
As expected from our observations in vivo, MSP stimulation did not 
increase osteoclast differentiation, and even demonstrated an inhibitory effect 
when added at early time points relative to the onset of differentiation (Figures 
4.S6C and 4.S6D). MSP was not sufficient for differentiation when added at any 
time during the differentiation process (Figure 4.S6E). This suggests that RANKL 
is required to prime these cells for cell fate determination and differentiation, 
similar to that of other factors which have been shown to activate osteoclasts 
(Itoh 2001; Ha 2011). The ability of these cells to resorb matrix as they 
differentiated was also tested. Interestingly, MSP was able to stimulate 
osteoclast resorption of RANKL-differentiated osteoclast precursor cells, even 
when added at very early time points (Figure 4.S6F). Together, these data 
suggest that RANKL is required for osteoclast differentiation, but can be 
dispensable for the resorptive activity of fully-differentiated osteoclasts when 
MSP is present. 
Because RANK signaling is thought to be required for osteoclast survival, 
we also questioned whether MSP could affect the survival of existing osteoclasts 
in the absence of RANKL. To determine this, osteoclasts were fully differentiated 
in the presence of M-CSF and RANKL. These factors were then removed from 





cultured for an additional 48 hours and osteoclast survival was determined by 
counting the number of TRAP+ cells present. While the number of surviving 
osteoclasts was reduced in all conditions tested without RANKL and M-CSF, the 
number of surviving osteoclasts was significantly augmented in the presence of 
MSP (Figure 4.6D). These experiments demonstrate that the MSP/Ron pathway 
does not promote osteoclast differentiation, but instead functions to stimulate 
osteoclast activity and survival. 
c-Src has been shown to be critical in the regulation of osteoclast survival, 
motility, cytoskeletal reorganization, and resorption ability (Boyce 1992; Izawa 
2012; Soriano 1991). To determine whether MSP/Ron signaling stimulates c-Src 
activity independently of RANK, we tested c-Src phosphorylation in the presence 
or absence of RANKL signaling. Addition of the RANKL antagonist to WT 
osteoclasts resulted in a decrease in phosphorylated c-Src. However, MSP was 
able to rescue the loss of phosphorylated c-Src, indicating that the MSP/Ron 
pathway functions as an alternative pathway of c-Src activation in the absence of 
RANKL signaling (Figures 4.6E and 4.6F). Taken together, these results suggest 
that Ron plays a critical role in a signaling pathway that is known to be essential 
for osteoclast activity (Figure 4.S6H). 
 
4.5.7 Ron expression in the host is required for ovariectomy- 
induced bone loss 
Pathways involved in tumor-driven osteolysis are also often implicated in 





MSP/Ron pathway in bone loss due to postmenopausal osteoporosis, we 
performed ovariectomies in WT and RonTK-/- mice and analyzed bone loss by 
dual-energy X-ray absorptiometry (DXA) and bone histomorphometry 28 days 
later. The ovarectomized RonTK-/- mice were more resistant to loss of bone 
mineral density (BMD), bone volume, and trabecular thickness, with a 
concomitant decrease in trabecular spacing as compared to WT mice or sham-
operated controls (Figures 4.7A-E). In fact, loss of Ron resulted in complete 
protection from osteoporosis, as RonTK-/- bones were not statistically different 
than sham-operated controls. There also was no difference in the bone 
histomorphometric parameters between sham-operated mice of either genotype, 
demonstrating that there are no basal differences in bone density in the Ron TK-
/- mice under normal physiologic conditions.  Importantly, treatment with 
ASLAN002 after ovary removal also completely prevented bone loss (Figures 
4.7A-E). These data further show that MSP/Ron activity is a critical pathway for 
osteoclast activation both in physiological and pathological states. 
 
4.6 Discussion 
4.6.1 Importance of MSP/Ron in human breast cancer 
Previous studies have indicated an important role for the MSP/Ron 
pathway in human breast cancer, as well as in many other cancers 
(Kretschmann 2010). Expression of components of the MSP/Ron pathway are 
highly significant, independent prognostic factors for metastasis and death in 





whose tumors overexpress the MSP/Ron pathway indicated that they have a 
significant increase in metastasis overall, as well as increased metastasis to the 
bone (Welm 2007). In fact, MSP is overexpressed in approximately 40% of 
breast cancers, indicating a substantial number of patients whose tumors have 
the potential for an interaction with Ron in the microenvironment leading to 
metastasis. Despite the importance of this pathway in breast cancer metastasis, 
little was understood regarding the ability of this pathway to promote bone 
metastasis - the most common site of metastasis in patients. 
In this study, we show that expression of MSP in breast cancer cells 
promotes tumor-induced osteolysis through activation of Ron in the host 
osteoclasts. The bone destruction caused by MSP-expressing tumors was not 
affected by inhibition of RANKL or TGFβ signaling, indicating a novel pathway of 
osteoclast activation. Additionally, we have demonstrated the potential for 
therapeutically targeting the MSP/Ron pathway; inhibition of Ron with two 
inhibitors and in several preclinical mouse models blocked tumor-induced bone 
destruction, even after osteolytic disease had been well established. Genetic 
deletion or pharmacological inhibition of Ron activity was also able to reduce the 
development of osteoporosis-associated bone loss, suggesting that 
therapeutically targeting this pathway could be valuable in multiple diseases 








4.6.2 Role of Ron in the osteoclast 
Ron expression in differentiated osteoclasts, and the dramatic increase in 
Ron mRNA expression as pre-osteoclasts differentiate into osteoclasts, was 
demonstrated several years ago (Yang 2008). However, the function of Ron in 
these cells was unknown. We have shown that Ron activation by MSP stimulates 
osteoclast survival and bone resorption. In addition, we have shown that Ron 
activity in osteoclasts leads to activation of c-Src and can function as an 
alternative pathway to c-Src activation in the absence of functional RANKL 
signaling. c-Src is responsible for several critical functions in the osteoclast, 
including cytoskeletal reorganization and the formation of the ruffled border, 
thereby fundamentally regulating the ability of an osteoclast to resorb bone 
(Boyce 1992). Deletion of c-Src in mice leads to severe osteopetrosis, despite 
the presence of mature osteoclasts, indicating that the disease developed due to 
a defect in osteoclast function and not a lack of differentiation (Soriano 1991). 
Similarly, the Ron TK-/- mice do not demonstrate a reduction in the number of 
osteoclasts but, under diseased conditions, demonstrate a defect in osteoclast 
function. This distinguishes the MSP/Ron pathway from others, such as RANKL, 
which demonstrate a combined effect on both differentiation and resorptive 
activity. 
In addition to promoting survival, RANK drives two key pathways in 
osteoclasts: differentiation and activation. RANK associates with c-Src and, 
together with αvβ3, leads to cytoskeletal reorganization and resorption. This 





(Izawa 2012). Based on our data, it is likely that Ron functions to activate c-Src in 
the absence of functional RANK signaling, while having no effect on RANK-
regulated pathways of differentiation. Although not critical during bone 
development (Ron TK-/- mice have normal bone histomorphometric parameters), 
the effects of aberrant Ron activation in osteoclasts become readily apparent in 
disease settings. This suggests that, while the MSP/Ron pathway is not 
absolutely necessary for osteoclast function, this pathway plays an important role 
in the modulation of osteoclast activity in the cancer setting and in the 
development of osteoporosis. 
 
4.6.3 Association of the MSP/Ron pathway with the vicious cycle 
The role of both RANKL and TGFβ in the “vicious cycle” is a well- 
established mechanism for osteoclast activation and has been shown to be 
crucial for the ability of many breast cancer cells to induce bone loss. Our data 
indicate that the MSP/Ron pathway functions in parallel to the RANKL and TGFβ 
pathways. While it is still a possibility that these pathways interact in some 
fashion, the evidence suggests that, in terms of their ability to activate 
osteoclasts, they function as separate, additive pathways in osteoclast activation. 
For example, control PyMT tumors and MDA-MB-231 cells demonstrated 
dependence on RANKL and TGFβ for their ability to induce osteolysis. However, 
when MSP is expressed (exogenously in PyMT tumors or MDA-MB-231 cells, or 
endogenously in DU4455 cells), the MSP/Ron pathway can bypass the 





destruction (Figure 4.6H). It will be interesting to further understand the interplay 
of these pathways in breast cancer-induced bone loss as well as in other bone 
diseases. 
 
4.6.4 Potential for Ron inhibitors as therapy against osteolysis 
Inhibition of the Ron pathway can be achieved through pharmacological 
inhibition of its tyrosine kinase activity, either directly with small molecule 
inhibitors or indirectly through ligand-blocking antibody approaches 
(Kretschmann 2010). It is not yet clear if both strategies of inhibition will prove 
beneficial, as Ron is known to have multiple isoforms that function in a ligand-
independent manner and may not be inhibited by ligand-blocking antibodies. 
Although several small molecule Ron kinase inhibitors are selective for Ron, 
most also inhibit the related Met kinase. Several of these Ron/Met inhibitors are 
being developed as potential anticancer agents and the Ron-selective 
ASLAN002 compound is currently in a Phase I clinical trial (NCT01721148) for 
metastatic cancer. Here we have shown that two small molecule inhibitors for 
Ron/Met, including ASLAN002, prevent osteolysis in several metastatic breast 
cancer models, even after osteolysis had initiated. The blockade in osteolysis 
phenocopied that seen in the RonTK-/- mice, strongly suggesting that the effect 
is through Ron inhibition. It will be interesting to determine whether combinatorial 
inhibition of Ron and RANKL would lead to an additive or synergistic effect in 





We focused on breast cancer because it is the most common cause of 
osteolytic bone metastasis. However, we also note that MSP is specifically 
overexpressed in others cancers that are often metastatic to bone and osteolytic, 
such as lung cancer and multiple myeloma (Figures 4.S7A and 4.S7B). 
Therefore, Ron inhibitors may be valuable as therapeutic agents in cancers other 
than those arising in the breast – perhaps in combination with other modulators 
of osteoclast activity such as denosumab or bisphosphonates (Lipton et al., 
2012). Moreover, as is the case with other inhibitors of osteoclast activity, Ron 
inhibitors may be applicable to other diseases that cause bone loss. Indeed, we 
have demonstrated that Ron inhibition was able to significantly reduce bone loss 
due to osteoporosis.  
 
4.7 Experimental procedures 
4.7.1 Tumor injections and X-ray analysis 
All procedures involving mice and experimental protocols were approved 
by the Institutional Animal Care and Use Committee (IACUC) of the University of 
Utah. The Ron TK-/- mice, which reside on the FVB background, were crossed 
with NOD.SCID mice for an immune-compromised mouse model. As a control, 
wild-type FVB mice were also crossed with NOD.SCID mice. The STK-/- mice, 
which are on a C57BL/6 background, were compared to wild-type C57BL/6 mice 
as controls. Mice for all experiments were 6 to 8 weeks of age. For intratibial 
injections, 1 x 105 (PyMT or DU4475) or 3 x 105 (MDA-MB-231) tumor cells were 





female FVB (PyMT) or NOD.SCID mice carrying various alleles of Ron. 
Osteolysis was assessed by X-ray radiography. Dissected hindlimbs from mice 
sacrificed at the final time point in each experiment were placed in the Kodak In-
vivo Multispectral Imaging System FX and exposed to X-ray radiography at 35 kV 
for 100 sec. Excess tumor tissue was removed from the bones prior to X-ray. 
Osteolytic lesions were quantified using Image J software (NCBI). All images 
were compared to the contralateral leg as an internal control. 
 
4.7.2 Microcomputed tomography imaging and bone 
 mineral density measurements 
Representative samples were imaged by microcomputed tomography 
(µCT, Skyscan) with volume rendering snapshots of the tibia. For the 
osteoporosis study, representative samples were imaged and presented as 
volume rendering snapshots of the axial view of the tibial metaphysis region. For 
bone mineral density (BMD) measurements, the right tibia was removed and 
fixed in 10% NBF overnight. The tibia were then scanned by dual-energy X-ray 
absorptiometry (DXA) using a Norland pDEXA densitometer (Norland Medical 
Systems). A region including the primary and secondary spongiosa was used to 
determine the BMD of the tibia. 
 
4.7.3 Tissue processing and immunohistochemical staining 
Hindlimb bones were excised from mice at the time of sacrifice and bones 





Corp.) for 8 days and embedded in paraffin for hematoxylin and eosin (H & E) or 
immunohistochemical staining. Osteoclast number was assessed as TRAP+ 
multinucleated cells containing 4 or more nuclei and reported as TRAP+ cells per 
field. Three sections per mouse and 5 fields per section were used for 
quantification with fields representing the entire length of the tibia. Tumor 
proliferation rate was reported as the number of cells which were positive for 
phospho-H3 staining compared to the number of unstained cells per field 
expressed as a percent. Three sections per mouse and 5 fields per section were 
used for quantification with analysis being restricted to within the bone marrow 
cavity. Immunohistochemical analysis was performed with heat-induced antigen 
retrieval in sodium-citrate buffer (Dako). Primary antibodies used were anti-TRAP 
at 1:50 (Santa Cruz, sc-30833), anti-Ki67 at 1:100 (Santa Cruz, sc-12202S), anti-
phosphoH3 at 1:100 (Cell Signaling, #9701), anti-NFATc1 at 1:50 (Santa Cruz, 
sc-13033), and anti-Ron at 1:250 (Santa Cruz, sc-322). Bones from mice lacking 
Ron were used as a negative control (Correll, 1997). Biotinylated secondary 
antibody was used with the EnVision+ system HRP kit (Dako) and nuclei 
counterstained with hematoxylin. 
 
4.7.4 Osteoclast resorption assay 
Bone marrow osteoclasts were generated from 6- to 8-week-old WT and 
Ron TK-/- mice. Briefly, bone marrow was isolated from hindlimb bones and 
plated in α-MEM media containing 10% heat-inactivated fetal bovine serum 





human macrophage colony-stimulating factor (hM-CSF) (PeproTech) for 24 
hours. Nonadherent cells were collected and frozen for later use. To assess 
resorption activity, bone marrow precursor cells were thawed and seeded at a 
density of 1 x 105 cells per well in BioCoat Osteologic slides (BD Biosciences) in 
α-MEM media containing 10% FBS and antibiotics. After adhering overnight, 
media was removed and media containing 33 ng/mL hM-CSF and 9 ng/mL 
muRANKL (R & D systems) was added. The medium was changed every 3 days 
depending on acidification, and the assay was terminated as indicated. 
Recombinant human MSP was prepared and added daily as indicated. Cells 
were removed with 6% bleach and slides were viewed microscopically using 
phase-contrast with 20x magnification. Osteolytic resorption area within 5 
representative fields was determined using Image J software. Experiments were 
performed in triplicate. Recombinant MSP was prepared as follows (to be 
described in detail elsewhere): Concentrated, serum-free media from an MCF7 
cell line engineered to overexpress MSP was cleaved with kallikrein (Invitrogen; 
4 ng of kallikrein/1 ug of supernatant protein at 370C for 2.5 hours). The reaction 
was diluted to 20 mL with 10 mM sodium phosphate, pH7.4 and loaded onto a 5 
mL HiTrap heparin column (Millipore) equilibrated with 20 mL of 10 mM sodium 
phosphate, pH7.4, at a rate of 1mL/min. The column was washed with 10mL of 
10mM sodium phosphate, pH7.4, at a rate of 1mL/min. The bound protein was 
eluted with 7mL of serial concentrations of NaCl in 10 mM sodium phosphate, 
pH7.4: 0.1M, 0.15M, 0.2M, 0.25M, 0.3M, 0.35M, 0.4M, 0.45M, and 2M. Each 





was run for MSP western analysis and ELISA analysis to determine purity and 
concentration.  
 
4.7.5 Osteoclast survival assay 
Bone marrow precursor cells were thawed and seeded at a density of 2 x 
105 cells per well in a 24-well plate containing glass coverslips in α-MEM media 
containing 10% FBS and antibiotics. After adhering overnight, media was 
removed and media containing 33 ng/mL hM-CSF and 9 ng/mL muRANKL was 
added. Cells were allowed to differentiate for 7 days with media changed every 3 
days. Coverslips were then imaged microscopically using phase contrast to 
determine osteoclast number in each well. To test survival, factor-containing 
media was removed and α-MEM media containing 10% FBS was added as well 
as MSP as indicated. Cells were cultured for an additional 48 hours, fixed with 
10% NBF for 10 minutes, and washed with 1x PBS. For TRAP fluorescent 
staining, the leukocyte acid phosphatase kit (Sigma) was used according to the 
manufacturer’s instructions, with the substitution of 200 µM ELF97 (Invitrogen) as 
a phosphatase substrate. Coverslips were incubated in TRAP solution for 15 
minutes at 37 degrees, washed with 1x PBS, and counterstained with DAPI. The 
number of multinucleated TRAP+ cells (containing 4 or more nuclei) within 5 
representative fields were included for quantification. Experiments were 







4.7.6 Murine RANKL ELISA 
Quantitative levels of murine RANKL in serum isolated from mice at the 
end-point of experiments was determined in triplicate by ELISA according to the 
manufacturer’s protocol (Quantikine immunoassay kit, R & D systems). 
 
4.7.7 Pharmacological inhibition in vitro and in vivo 
For in vitro experiments, OSI-296 (OSI pharmaceuticals) and ASLAN002 
(BMS-777607; Selleck) were dissolved in DMSO. Inhibitors were added to in vitro 
osteoclast assays at a final concentration of 10 µM daily for 3 days beginning on 
day 9 of the experiment. muRANK-Fc (Amgen) was provided as a stock of 4.1 
mg/mL in PBS and was added to in vitro assays at a final concentration of 10 
µg/mL daily as indicated.  
For in vivo experiments, the OSI-296 inhibitor was dissolved in 40% 
Trappsol with 0.01M HCl and mice were treated at a concentration of 200 mg/kg 
daily by oral gavage. Treatment began either 3 days after tumor cell injection for 
prophylactic experiments, or 3 weeks after tumor cell injection for therapeutic 
experiments. ASLAN002 was dissolved in 70% PEG400 with 1x PBS and mice 
were treated at a concentration of 50 mg/kg daily by oral gavage. muRANK-Fc 
was given at a concentration of 10 mg/kg every 3 days by intraperitoneal 
injection. For the osteoporosis study, mice were treated beginning on the day 
after ovary removal. The treatment regimen for OSI-296 was 200 mg/kg every 
other day by oral gavage. ASLAN002 was administered at 50 mg/kg every other 





4.7.8 Cell culture 
The DU4475 cell line (ATCC) was maintained in RPMI (Hyclone) with 10% 
FBS and antibiotics. The MDA-MB-231 cell line (ATCC) was maintained in RPMI 
with 10% FBS, antibiotics, and HEPES (Sigma). MC3T3-E1 subclone 4 cells 
(ATCC) were maintained in α-MEM with 10% FBS and antibiotics. PyMT tumors 
were isolated and transduced as previously described and frozen for later use 
(Welm et al., 2005; Welm et al., 2007). Cells were thawed and grown for 2 to 3 
days in DMEM/F12 with 10% FBS, antibiotics, insulin (Gibco), hydrocortisone, 
and epidermal growth factor prior to injections. MDA-MB-231 cells were 
transduced with replication-defective retroviruses containing the expression 
vector pMSCVpuro or MSCVpuro-MSP, and infected cells were selected with 
puromycin. 
 
4.7.9 Western blot analyses 
Cells were serum starved (0.5% FBS) for 3 hours prior to lysate collection. 
Inhibitors were added 1 hour prior to lysis and MSP was added 15 minutes prior 
to lysis when indicated. Cells were washed with 1x PBS and harvested in lysis 
buffer (25mM Tris-HCl, pH 7.5, 0.42 M NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 1 
mM DTT, 25% sucrose, and 0.1% Triton X-100) plus 100x protease arrest 
(Bioscience) and 100x orthovanadate. Primary antibodies used for 
immunoblotting include: anti-MSP (Santa Cruz, sc-6090) at a 1:250 dilution, anti-
pan Akt (Cell Signaling, #4691S) at a 1:1000 dilution, anti-pan Erk (Cell 





at a 1:500 dilution, anti-phospho Erk (Cell Signaling, #4370S) at a 1:500 dilution, 
anti-Src (Cell Signaling, #2110) at a 1:500 dilution, and anti-phospho Src (Y416) 
(Cell Signaling, #2113) at a 1:500 dilution. The secondary antibodies used were 
HRP-conjugated anti-goat IgG (Santa Cruz) and anti-rabbit IgG (Santa Cruz). 
Chemiluminescent signals were detected using Immun-Star HRP (BioRad). 
 
4.7.10 In vivo bone labeling and histomorphometry 
To label bones, mice were intraperitoneally injected with 20 mg/kg of 
calcein (Sigma-Aldrich) or 30 mg/kg of Alizarin Complexone (Sigma-Aldrich) in a 
2% sodium bicarbonate solution. Mice 6 to 8 months of age were labeled 8 days 
and 2 days prior to euthanasia, respectively. Tibia were fixed in 70% ethanol, 
embedded in methylmethacrylate, and sectioned. Bone histomorphometry on H 
and E sections and bone labeled sections were performed as previously 
described (Parfitt et al., 1987). Analysis of bone volume (BV/TV) and trabecular 
spacing (Tb. Sp.) were performed on the metaphyseal region of tibia sections 
stained with H and E. Bone formation rate (BFR) per bone surface (BS) and 
mineral apposition rate (MAR) of trabeculae were calculated within the 
metaphyseal region of the tibia. For all histomorphometry, three sections per 
mouse with 4 to 5 mice per group were analyzed. Analysis was performed using 








4.7.11 Statistical Analysis 
Data are shown as mean +/- SEM. All experiments were analyzed using 2-
tailed, unpaired, Student’s t test using Prism 6 (GraphPad Software). 
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Figure 4.1. MSP increases tumor-driven osteolysis through host Ron 
activity. (A) Microcomputed tomography (µCT) of bone lesions in the tibia 21 
days post tumor cell injection. Scale bar, 2mm. (B) Quantification of osteolytic 
area in tibias from mice ex vivo using high resolution X-ray analysis (n=10) 42 
days post tumor cell injection. (C) Tumor growth in tibias, determined by caliper 
measurements. (D) Proliferation rate of PyMT control and MSP-expressing tumor 
cells expressed as the percent of cells staining positive for phospho-Histone H3. 
(E) TRAP staining on sections of tumor-bearing bones from each experimental 
group. Scale bar, 100 µm. (F) Quantification of TRAP+ osteoclasts in each 
experimental group (n=5-7 per group). Data in the figure represent mean +/- 

















Figure 4.2. Ron is required for tumor-driven osteolysis of human breast 
cancer. (A) Representative X-ray images of DU4475 bone lesions in NOD.SCID/ 
WT or NOD.SCID/Ron TK-/- mice, 42 days post tumor cell injection. (B) 
Quantification of osteolytic area from tibial bone lesions (n=5). (C) TRAP staining 
on sections of tumor-bearing bones from each experimental group. Scale bar, 
100 µm. (D) Quantification of TRAP+ osteoclasts in each experimental group 
(n=3-4). (E) Proliferation rate of DU4475 tumor cells in the bone (n=3-4). ns = not 
significant. Data in the figure represent mean +/- SEM; p values were based on 




















Figure 4.3. Ron inhibition reduces MSP tumor-induced osteolysis in 
prophylactic and adjuvant settings. (A) X-ray images of PyMT-MSP bone 
lesions from mice treated with OSI-296. Treatment began 3 days post tumor cell 
injection for pre-osteolysis treatment and 3 weeks post injection for post 
osteolysis treatment. Mice were sacrificed 42 days post injection for analysis. (B) 
X-ray images of PyMT-MSP bone lesions from mice treated with ASLAN002. 
Treatment began 3 days post tumor cell injection. Mice were sacrificed 21 days 
post injection for analysis. (C) Quantification of osteolytic area in PyMT-MSP 
bone lesions from mice treated with OSI-296 (n=7-10 per group). (D) 
Quantification of osteolytic area in PyMT-MSP bone lesions from mice treated 
with ASLAN002 (n=4-5 per group). (E) Representative X-ray images of DU4475-
induced bone lesions from mice treated with ASLAN002. Treatment began 3 
days post tumor cell injection and mice were sacrificed 28 days post injection for 
analysis. (F) Quantification of osteolytic area in DU4475 bone lesions from mice 
in each experimental group (n=5). (G) ELISA-based quantification of serum 
RANKL concentration from mice in each experimental group (n=3). Data in the 
figure represent mean +/- SEM; p values were based on Student’s t test. * p = 
















Figure 4.4. MSP tumor-induced osteolysis is not dependent on RANKL or 
TGFβ signaling. (A) Representative X-ray images of PyMT-MSP bone lesions 
from mice treated with muRANK-Fc. Treatment began 3 days post tumor cell 
injection and mice were sacrificed 42 days post tumor cell injection for analysis. 
(B) Quantification of osteolytic area in bone lesions from mice in each 
experimental group (n=16 per group for WT mice and 3 to 5 per group for Ron 
TK-/- mice, respectively). (C) TRAP staining of tumor-bearing bones from each 
experimental group. Scale bar, 100 µm. (D) X-ray images of PyMT bone lesions 
arising from tumors in the presence or absence of TGFβRII. Mice were sacrificed 
38 days post tumor cell injection for analysis. (E) Quantification of osteolytic area 
in bone lesions from mice in each experimental group (n=5). Data in the figure 
represent mean +/- SEM; p values were based on Student’s t test. ** p = 0.0041, 














Figure 4.5. Expression of MSP in human breast cancer increases tumor-
induced osteolysis and overrides dependence on RANKL signaling. (A) 
Western blot showing MSP protein levels secreted into the media of parental, 
control, and MSP-overexpressing MDA-MB-231 cells. (B) X-ray images of bone 
lesions from NOD.SCID mice treated with muRANK-Fc or OSI-296 3 days post 
tumor cell injection. Mice were sacrificed 30 days post tumor cell injection for 
analysis. (C) Quantification of osteolytic area from bone lesions in mice from 
each experimental group (n=5). Data in the figure represent mean +/- SEM; p 



















Figure 4.6. MSP promotes osteoclast activity and survival through 
activation of Src and Akt signaling pathways. (A) Quantification of the 
resorption area from each experimental group (n=4). Bone marrow precursor 
cells were differentiated in the presence of M-CSF and RANKL for 9 days. 100 
pg/mL of MSP was added daily beginning on day 9 with the experiment ending 
on day 12. (B) Quantification of the resorption area arising from WT and Ron TK-
/- bone marrow precursor cells differentiated in the presence of M-CSF and 
RANKL for 9 days (n=3). 10 µg/mL of muRANK-Fc was added daily beginning on 
day 9 with the experiment ending on day 12. (C) Quantification of the resorption 
area (n=3). WT bone marrow precursor cells were seeded on osteologic slides 
and differentiated in the presence of M-CSF and RANKL for 9 days. muRANK-Fc 
at a concentration of 10 µg/mL and/or ASLAN002 at a concentration of 10 µM 
was added daily beginning on day 9 with the experiment ending on day 12. (D) 
Quantification of the number of TRAP+ osteoclasts per well from each 
experimental group (n=3). WT bone marrow precursor cells were differentiated in 
the presence of M-CSF and RANKL for 7 days. M-CSF and RANKL were 
washed out and 100 pg/mL of MSP was added daily, beginning on day 7, and 
continued for 48 hours. TRAP+ cells were identified by fluorescent TRAP stain 
and cells with 4 or more nuclei were counted. (E) Western blots of osteoclast 
lysates from WT cells treated with MSP, muRANK-Fc, and /or ASLAN002. (F) 
Model of MSP/Ron function in the bone microenvironment. Data in the figure 
represent mean +/- SEM; p values were based on Student’s t test. *p < 0.04, **p 











Figure 4.7. Loss of Ron activity protects from osteoporotic bone loss. (A) 
µCT images of the proximal tibia (axial view of the metaphyseal region) from WT 
and Ron TK-/- mice following ovariectomy (OVX) or sham operation. WT OVX 
mice were treated with ASLAN002 beginning 1 day postovariectomy. Mice were 
sacrificed 28 days postovariectomy for analysis. (B) Quantification of bone 
mineral density in the metaphyseal region of the tibia determined by bone 
histomorphometry analysis (n=5). (C) Quantification of trabecular bone volume in 
the tibia expressed at percent per total volume and determined by bone 
histomorphometry analysis (n=5). (D) Quantification of trabecular separation in 
the tibia (n=5). (E) Representative sections of the tibia from each group stained 
for H and E. Data in the figure represent mean +/- SEM; p values were based on 













Figure 4S1. Genetic deletion of Ron has no effect on osteoblast activity (A) 
Quantification of TRAP+ osteoclasts from normal, uninjected WT and Ron TK-/- 
mice (n=5). (B) Bone formation as observed by calcein and Alizarin double 
labeling, scale bar = 100 µm for images at 4x magnification and 50 µm for inset 
images at 40x magnification. (C) Mineral apposition rate determined by bone 
histomorphometric analysis in WT and RonTK-/- mice (n=4-5). (D) Bone 
formation rate per total bone surface in WT and RonTK-/- mice (n=4-5). (E) 
Mineral apposition rate in WT and STK-/- mice (n=4-5). (F) Bone formation rate 
per total bone surface in WT and STK-/- mice (n=4-5). (G) Tissue sections 
stained for Ron in normal, uninjected WT and STK -/- mice. Both osteoclasts and 
chondrocytes stain positive for Ron. (H) Western analysis for Ron and phospho-
Ron in the MCF10A-Ron and MC3T3-E1 cell lines. Cells were grown in the 
presence of 10% serum to 90% confluency. The media was then exchanged for 
media containing 0.5% serum and the cells were cultured overnight. 100 pg/mL 
MSP was added for 15 minutes and lysates were prepared. The MCF10A cell 
line overexpressing Ron serves as the positive control for Ron and phospho-Ron 
expression while the MC3T3-E1 cell line demonstrates the lack of Ron 













Figure 4S2. MSP-driven osteolysis does not depend on T cells (A) mRNA 
expression levels of MSP, Ron, and matriptase in a panel of human breast 
cancer cell lines. Dotted lines depict average expression level for each gene. (B) 
TRAP staining of normal, uninjected NOD.SCID:WT and NOD.SCID:Ron TK-/- 
bones. Scale bar, 100 µm. (C) Quantification of TRAP+ osteoclasts from normal, 
uninjected bones (n=4). (D) X-ray images of bone lesions from each group. 
PyMT tumor cells expressing MSP were injected into the tibia of NOD.SCID: WT 
or NOD.SCID:Ron TK-/- mice. Mice were sacrificed 28 days post tumor cell 
injection for analysis. (E) Quantification of osteolytic area of bone lesions in mice 
from each experimental group (n=3-5). (F) Growth curves of PyMT-MSP bone 
lesions for each experimental group. Tumor size was determined by caliper 
measurements. (G) TRAP staining of bone tumors from each experimental 
group. Scale bar, 100 µm. (H) Quantification of TRAP+ osteoclasts from PyMT-
MSP bone tumors of each experimental group (n=4). Data in the figure represent 














Figure 4S3. Ron inhibitors do not significantly reduce tumor growth (A) X-
ray images of PyMT control bone lesions treated with OSI-296. (B) Quantification 
of osteolytic area in mice with bone lesions treated with OSI 296 (n=8,5). Control 
tumor cells were injected into the tibia of WT mice, treatment began 3 days post 
tumor cell injection. Mice were sacrificed 42 days post injection for analysis. (C) 
Proliferation rate for PyMT control tumors indicated as percent cells staining 
positive for phospho-H3 (n=3). (D) Tumor growth curve (n = 9 - 13) and 
proliferation rate (n = 5,4) for PyMT-MSP bone lesions treated with OSI-296. 
PyMT-MSP tumor cells were injected into the tibia of WT mice and treatment 
began 3 days post tumor cell injection for preosteolysis treatment and 3 weeks 
post injection for postosteolysis treatment. Mice were sacrificed 42 days post 
injection for analysis. (E) Tumor growth curve and proliferation rate for PyMT-
MSP bone lesions treated with ASLAN002 (n=5,4). PyMT-MSP tumor cells were 
injected into the tibia of WT mice and treatment began 3 days post tumor cell 
injection. Mice were sacrificed 21 days post tumor cell injection; tumor size was 
determined by caliper measurements (n > 0.28). (F) Proliferation rate of PyMT-
MSP tumors treated with OSI-296 (n=3). (G) Tumor growth curve and 
proliferation rate for DU4475 bone lesions from each experimental group treated 
with ASLAN002 (n=5). DU4475 tumor cells were injected into the tibia of 
NOD.SCID/ Ron TK+/+. Treatment began 3 days post tumor cell injection and 
mice were sacrificed 42 days post tumor cell injection for analysis (n > 0.44). 
Data in the figure represent mean +/- SEM; p values were based on Student’s t 











Figure 4S4. Ron inhibitors do not affect osteoclast number or osteoblast 
activity (A) TRAP staining of PyMT-MSP bone tumors from mice treated with 
OSI-296 either 3 days post tumor cell injection for preosteolysis or 3 weeks post 
injection for postosteolysis treatment. Mice were sacrificed 42 days post injection 
for analysis. (B) Quantification of TRAP+ osteoclasts from bone tumors in each 
experimental group (n=4). (C) Bone formation as observed by calcein and 
Alizarin double labeling, scale bar, 100 µm for images at 4x magnification, and 50 
µm for inset images at 40x magnification. (D) Mineral apposition rate in normal, 
uninjected animals treated with ASLAN002 (n=4 - 5). (E) Bone formation rate per 
total bone surface in animals treated with ASLAN002 (n=4 - 5). Data in the figure 













Figure 4S5. Neither RANKL antagonism nor the lack of TGFβ significantly 
affects tumor growth (A) Growth curve from bone lesions treated with 
muRANK-Fc in each experimental group. Tumor cells were injected into the tibia 
of WT or Ron TK-/- mice. Treatment began 3 days post tumor cell injection. 
Tumor size was determined by caliper measurements. (B) Ron and NFATc1 
staining of tissue sections from PyMT-MSP tumor-bearing bones treated with 
muRANK-Fc. Arrows indicate positively stained osteoclasts, scale bar = 50 µm. 
(C) Growth curve of either PyMT wildtype or TGFβRII-/- bone lesions in mice 
from each experimental group. Tumor cells were injected into the tibia of WT 
















Figure 4S6. MSP increases osteoclast activity independently of RANKL 
while having no effect on osteoclast differentiation (A) Representative 
images of resorption pits from WT and Ron TK-/- osteoclasts in the presence and 
absence of MSP. (B) Quantification of resorption area in each experimental 
group (n=3). WT bone marrow precursor cells were seeded on osteologic slides 
and differentiated in the presence of M-CSF and RANKL for 9 days. muRANK-Fc 
at a concentration of 10 µg/mL and/or OSI-296 at a concentration of 10 µM was 
added daily beginning on day 9, ending on day 12. (C) Timeline describing the 
addition of MSP during differentiation. M-CSF and RANKL were present 
continuously beginning on day 1 until experimental analysis. (D) Quantification of 
TRAP+ osteoclasts in each experimental group (n=3). WT bone marrow 
precursor cells were seeded on glass coverslips and differentiated in the 
presence of M-CSF and RANKL. 100 pg/mL of recombinant MSP was added 
daily, beginning at the time points indicated. TRAP+ cells were identified by 
fluorescent TRAP stain and cells with 4 or more nuclei were counted. (E) 
Quantification of the number of TRAP+ osteoclasts per well for each 
experimental group (n=3). WT bone marrow precursor cells were seeded onto 
glass coverslips and differentiated in the presence of M-CSF and RANKL. 
RANKL was removed from the media and 100 pg/mL of recombinant MSP was 
added at the indicated time points with the experiment terminating on day 9. (F) 
Quantification of resorption area in each experimental group (n=3). WT bone 
marrow precursor cells were seeded on osteologic slides and differentiated in the 
presence of M-CSF and RANKL for 9 days. 100pg/mL of recombinant MSP was 
added at the indicated time points with the experiment terminating on day 12. (G) 
Timeline describing the addition of MSP and removal of RANKL to determine 
osteoclast survival. Cells were cultured in the presence of M-CSF and RANKL for 
7 days. These factors were then removed from the culture and 100 pg/mL of 
MSP was added daily, beginning on day 7, and continued for 48 hours. (H) 
Model of signaling pathways activated downstream of Ron activation in 
osteoclasts. Data in the figure represent mean +/- SEM; p values were based on 















Figure 4S7. MSP is highly expressed in other bone-metastatic cancers 
when compared to normal cell types (A) Expression of MSP in normal plasma 














5.1 Ron function in osteoclasts 
 Stem cell-derived tyrosine kinase (STK) is the murine homologue of the 
human RON gene and was originally isolated from mouse hematopoietic stem 
cells (Ronsin 1993). STK protein was also shown to be expressed on resident 
peritoneal macrophages, suggesting a role for STK in multiple cell types from the 
monocytic lineage (Iwama 1995). Based on this evidence, Kurihara et al. 
hypothesized that STK may be expressed on osteoclasts as well, given that they 
are derived from similar precursor cells. STK was found to be expressed on 
osteoclasts differentiated with IL-3 and vitamin D3. The addition of MSP to these 
cells to in vitro cultures induced contraction and formation of the ruffled border, 
increased resorption, and caused redistribution of Src to the ruffled border 
(Kurihara 1996). Ron was then shown to be expressed on osteoclasts cultured 
from human bone marrow cells. As was demonstrated in murine osteoclasts, 
addition of MSP to human osteoclasts resulted in a cytoplasmic contraction, 





In addition, MSP was shown to have no effect on osteoclast differentiation or 
DNA synthesis in osteoclast progenitor cells, in contrast to functions of HGF 
(Kurihara 1998). 
 My data agree with the original observations that MSP has no critical role 
in osteoclast differentiation but has a marked effect on osteoclast resorption 
(Figures 4.S6D and 4.S6F). I have significantly extended these findings by 
showing that the lack of, or inhibition of, Ron kinase activity results in a significant 
reduction in resorption activity. I also showed that MSP can prolong survival of 
osteoclasts in the absence the key osteoclast cytokines M-CSF and RANKL. 
Importantly, I have shown that the ability of MSP to induce both osteoclast 
activity and survival is independent of RANKL signaling but requires c-Src 
activity. These results demonstrate that, at least in part, activation of Ron on 
osteoclasts by MSP results in downstream Src signaling. 
c-Src has been implicated in several key osteoclast functions including 
cytoskeletal reorganization, podosome assembly, and osteoclast survival. Src-/- 
mice have normal osteoclast numbers but develop severe osteopetrosis due to 
inactivity of these osteoclasts (Soriano 1990). Given the importance of c-Src in 
osteoclast activation, the ability of Ron to augment c-Src activity could explain 
how Ron functions to stimulate osteoclast activity. c-Src is known to signal 
downstream of RANK by associating with TRAF6. The ability of Ron to activate 
Src presents an explanation for osteoclast activity that is independent of RANKL, 





 The mechanisms by which Ron promotes osteoclast survival and activity 
are still under investigation, but plausible hypotheses can be gleaned from our 
knowledge of Ron function in other cell types. Ron signaling in various normal 
cells is classically mediated by RAS-ERK and PI3K-AKT pathways. For signaling 
activation, the interaction of Ron with adaptor proteins such as growth factor 
receptor-bound protein 2 (GRB2) is the first step in bridging Ron with 
downstream signaling cascades (Chaudhuri 2011; Li 1995). Various cytoplasmic 
effector molecules such as phospholipase C γ (PLCγ), PI3K, Src, 14-3-3, and Cbl 
physically interact with Ron through the C-terminal docking site (Yao 2013). 
During carcinogenesis, Ron has also been shown to activate NF-kB and signal 
transducer and activator of transcription (STAT) pathways (Park 2011; Xu 2005). 
In keratinocytes, Ron has been shown to regulate integrins via 14-3-3 proteins, 
which then regulate adhesion and migration of these cells. Stimulation of 
keratinocytes with MSP leads to phosphorylation of both Ron and α6β4 integrin 
and the formation of 14-3-3 binding sites within these proteins. Dimeric 14-3-3 
proteins then mediate the relocation of α6β4 integrins, concomitant activation of 
α3β1 integrin, and its relocalization from the plasma membrane to focal contacts 
over the migrating front, thereby culminating in cell spreading and migration 
(Santoro 2003). Interestingly, the Ron kinase does not directly activate α6β4, 
suggesting that another kinase, possibly a Src-like kinase, may be involved. The 
mechanism regulating activation of α3β1 in this context is unclear; however, the 
proposed model involves Ron signaling and 14-3-3/α3β1 complexes being 





focal contacts and regulate actin-myosin driven processes (Santoro 2003). The 
mechanisms underlying the ability of integrins to transition from a mechanical 
adhesion complex to signaling complexes are unclear; however, this evidence 
suggests that Ron is capable of regulating adhesion and migration through the 
regulation of integrins. 
Several integrins are involved in osteoclast binding to bone matrix 
proteins, including αvβ3 (binds to osteopontin, vitronectin, and bone sialoprotein), 
αvβ5 (binds to fibronectin), and α2β1 (binds to collagen) (Schneider 2011). Of 
these, αvβ3 has been shown to be the predominant integrin found on 
osteoclasts, and inhibition of αvβ3 blocks osteoclast attachment to the bone 
matrix, as well as osteoclast-mediated bone resorption (Ross 1993). αvβ3 
signaling has also been shown to be critical for creation of the resorptive ruffled 
membrane, regulation of osteoclast spreading, and overall organization of the 
cytoskeleton. αvβ3 has also been shown to be important for activation of c-Src, 
c-Cbl, and the GTPases Rho and Rac, all of which are necessary for the 
cytoskeletal reorganization important to osteoclast function (Schneider 2011). 
Because Ron has the ability to activate and regulate integrins in other cell 
types, such as keratinocytes, it is possible that Ron functions to regulate integrins 
in osteoclasts as well. Activation of integrins could explain the ability of MSP/Ron 
to significantly increase osteoclast resorption. This may also explain why addition 
of MSP to osteoclasts is able to cause relocalization of c-Src to the ruffled border 
and cytoplasmic contraction. RANK has been shown to interact with αvβ3 via c-





that Ron regulates osteoclast function independently of RANK but via activation 
of similar, critical pathways. Finally, Ron has been shown to promote survival of 
various cancer cells through MAPK and PI3K signaling (Danilkovitch 2000). The 
activation of PI3K leads to activation of Akt, which has been shown to enhance 
cell survival in osteoclasts, suggesting the possibility of a similar mechanism for 
Ron regulating survival in osteoclasts (Wong 1999). 
 While I have clearly demonstrated the ability of Ron to activate c-Src in 
osteoclasts, much more work is needed to determine the signaling pathways 
downstream of Ron in osteoclasts and the functions they regulate. Determining 
the pathways involved will also allow for the discovery of transcription factors 
regulated by MSP/Ron to regulate osteoclast gene expression, furthering our 
understanding of osteoclast biology and how MSP/Ron signaling culminates in a 
transcriptional response. It is likely that regulation of PI3K/Akt by Ron functions in 
osteoclast survival but this still needs to be determined. Utilizing docking domain 
mutants of Ron that alter downstream signaling could help determine the 
pathways involved in specific functions within osteoclasts (Iwama 1996; Ponzetto 
1994), especially if used in a rescue setting within the Ron TK-/- osteoclasts. 
In addition to the need for a better understanding of signaling pathways in 
regulation of osteoclast activity, the osteoclast itself (and structures important to 
its function) needs to be analyzed in much greater detail. Determining whether 
MSP has an effect on formation of the ruffled border, organization of podosomes 
and/or the assembly of actin-associated proteins will aid in determining potential 





assembly appears to be generally normal in Ron TK-/- osteoclasts, this needs to 
be analyzed utilizing more technical microscopy with live imaging and antibodies 
specific to actin-associated proteins to determine whether there are any 
perturbations in actin assembly or the recruitment of these proteins. Analysis of 
acid production and vesicle formation may also give clues as to why osteoclasts 
are much more active upon stimulation by MSP. 
 
 
5.2 Potential for Ron inhibitors in clinical trials 
 Patients with bone metastases develop skeletal-related events (SREs) 
defined as a pathologic fracture, requirement for surgical intervention or palliative 
radiotherapy, hypercalcemia, and/or spinal cord compression. SREs are 
associated with significant loss of mobility, pain, and reduced quality of life, and 
negatively affect survival (Coleman 2001). New therapies that prevent and/or 
delay SREs, reduce bone pain, and improve quality of life are much needed. 
 Currently, bisphosphonates are the established standard of care for 
patients with bone metastases. Bisphosphonates are potent inhibitors of 
osteoclast-mediated bone resorption through several mechanisms, including 
induction of osteoclast apoptosis and reduction of osteoclast activity (Petrut 
2008). The clinical efficacy of bisphosphonates primarily stems from two key 
properties: their ability to bind strongly to bone mineral, and their inhibitory effects 
on mature osteoclasts (Russell 2008). Their strong attachment to bone gives 
bisphosphonates the unique property of selective uptake by their intended target 





surfaces brings them into close contact with osteoclasts and other cells in the 
bone. During bone resorption, the acidic environment created by the osteoclast in 
the resorption lacuna is thought to allow the dissociation of bisphosphonates 
from the hydroxyapatite (Ebetino 1998). The bisphosphonates are then taken up 
by osteoclasts within intracellular endocytic vesicles. The bisphosphonates used 
as standard of care currently, such as zoledronic acid, contain nitrogen in the 
side chain of their chemical structure. These nitrogen-containing 
bisphosphonates act principally by inhibiting farnesyl pyrophosphate synthase, 
thereby preventing the posttranslational modification (prenylation) of small 
guanosine triphosphate-binding proteins that are essential for osteoclast function 
and survival (Russell 2008; Baron 2011). 
Treatment with zoledronic acid was shown to reduce the risk of developing 
a SRE by 41%, in addition to reducing bone pain. Treatment also reduces 
biomarkers of bone turnover such as urinary amino-terminal cross-linked 
telopeptides of type I collagen (uNTx) and bone-specific alkaline phosphatase 
(BSAP) by 68% and 37%, respectively (Petrut 2008; Stopeck 2010). Despite its 
efficacy, zoledronic acid is not without side effects. SREs still occur in a large 
proportion of patients despite therapy (Rosen 2001; Rosen 2003). Osteonecrosis 
of the jaw is a rare condition that occurs in patients treated with 
bisphosphonates, particularly with use of nitrogen-containing bisphosphonates. 
Nephrotoxicity has been shown to be associated with bisphosphonate therapy 
and the risk increases with extended treatment, so careful monitoring of 





(Chang 2003; Perazella 2008). Additionally, acute-phase reactions (flu-like 
symptoms) to intravenous bisphosphonate infusions occur frequently and require 
treatment with analgesics and antipyretics (Stopeck 2010). 
 The identification of the RANK/RANKL pathway, and the realization of its 
importance in osteoclasts, opened up the possibility for new targeted agents for 
treatment of osteolysis. Denosumab (Xgeva or Prolia), a fully human monoclonal 
antibody targeting RANKL, was developed and is now FDA approved. 
Denosumab prevents RANKL from binding to RANK and, in doing so, inhibits the 
development, activation, and survival of osteoclasts (Baron 2011). A phase III 
study comparing denosumab with zoledronic acid in patients with breast cancer 
bone metastases was performed, using the delay or prevention of SREs as an 
endpoint. Denosumab reduced the risk of developing multiple SREs by 23% and 
delayed the time to first on-study SRE by 18% compared with zoledronic acid. In 
addition, denosumab reduced the levels of bone turnover markers: uNTx was 
reduced by 80% and BSAP was reduced by 44% (Stopeck 2010). A meta-
analysis on three separate phase III trials involving breast cancer, prostate 
cancer, and multiple myeloma demonstrated the superiority of denosumab as 
compared to zoledronic acid in reducing the risk of the first on-study SRE by 17% 
(Lipton 2012). While denosumab does appear to be more efficacious than 
zoledronic acid, it is also much more costly and has a significantly higher risk of 
hypercalcemia in patients with low renal clearance (Qi 2013). Osteonecrosis of 
the jaw is still a concern, though the incidence in patients receiving denosumab is 





this advance in treatment, denosumab does not completely block the bone 
destruction caused by bone metastases and, more importantly, neither 
bisphosphonates nor denosumab affects disease progression or overall survival, 
underlining the fact that improved therapies are still needed. 
 Currently, there is one clinical trial open and one trial completed studying 
Ron inhibitors in cancer patients. The recently completed trial, NCT01119456, 
tested the safety and dosing of IMC-RON8 (namatumab) in patients with 
advanced solid tumors. IMC-RON8 is a monoclonal antibody that prevents the 
binding of MSP to Ron. While the results of the trial are not yet available, 
preclinical studies showed that IMC-RON8 blocked MSP-dependent Ron 
phosphorylation and downstream signaling in pancreatic cancer cell lines, 
inhibited MSP-driven cell migration, and sensitized these cells to treatment with 
the HDAC inhibitor panobinostat (Zou 2013). The second trial, NCT01721148, is 
a phase I trial studying the effects of ASLAN002 (BMS777607) in advanced or 
metastatic patients with solid tumors. ASLAN002, one of the drugs I used in my 
studies, is a small molecule tyrosine kinase inhibitor primarily targeting Ron and 
Met (Schroeder 2009). This inhibitor was originally developed as a Met inhibitor 
and has been shown in preclinical studies to inhibit a metastatic phenotype in 
prostate cancer cell lines and a mouse model of sarcoma (Dai 2010; Dai 2012). 
Despite the focus on Met as the target for this inhibitor, it is about twice as 
efficacious against Ron (IC50 of 1.8 nM for Ron vs. 3.9 nM for Met) (Schroeder 
2009). Indeed, I have demonstrated that this drug successfully inhibited MSP-





bone loss due to osteoporosis (Chapter 4). Because the results obtained using 
ASLAN002 were phenocopied in experiments performed using Ron knockout 
mouse models, I believe that my results with ASLAN002 are primarily the result 
of Ron inhibition. The next step in utilizing our knowledge of Ron biology for 
therapy is to translate my research results to clinical trials (see Appendix). 
However, there are many interesting questions that remain regarding the biology 




5.3 Future preclinical studies of MSP/Ron function 
While my data have convincingly demonstrated Ron as a potential 
therapeutic target and ASLAN002 as an efficacious and relatively non-toxic drug 
in mouse models of breast cancer, there are still questions remaining. Because 
tumors overexpressing MSP were more osteolytic in mouse models than non-
MSP tumors, it is possible that the expression level of MSP in patient tumors may 
correlate with their bone destructive ability. These data also suggest a potential 
need for patient selection, or at least stratification, based on MSP expression 
levels. Currently, there are no standardized techniques to measure or stain for 
MSP protein expression in tumors. One possible method is development of an 
immunohistochemical (IHC) stain for MSP in tumors, and standardized qualitative 
measurements for the staining intensity. However, MSP is a secreted protein and 
it is possible that a substantial amount of tumor-produced MSP will be secreted 





leading to inaccurate measurements. Another potential method is measuring the 
amount of MSP in patient serum or tumor biopsies by enzyme-linked 
immunosorbent assay (ELISA). While this method has the potential for much 
more accurate measurements, it is unclear whether the endogenous, inactive 
forms of MSP produced by the liver will overwhelm the signal from active MSP 
produced by the tumor. If so, this could result in high background levels and a 
low signal-noise ratio. However, there are results from two separate studies 
suggesting that changes in MSP concentrations within human serum can be 
detected. In the first study, the investigators used glycoproteomic analysis 
coupled with a 2D-LC-MALDI mass spectrometry system to identify potential 
biomarkers of osteoarthritic progression (Fukuda 2012). Plasma was isolated 
from patients with osteoarthritis of the knee, who were determined to be either 
progressors or non-progressors based on changes in radiographic criteria. The 
samples were then analyzed to identify proteins whose concentration increased 
significantly during progression. MSP was identified as one of the biomarkers in 
this study, demonstrating a significant increase in patients whose disease was 
progressing (Fukuda 2012). The second study involved detection of polymorphic 
alleles of MSP that have been identified in genome-wide association studies as 
significantly linked to susceptibility to inflammatory bowel diseases (Kauder 
2013). The investigators were able to demonstrate differences in the MSP protein 
concentration in patient serum that correlated with their genotype at the 
polymorphic allele. Taken together, these data suggest that it is possible to 





has developed both IHC and ELISA assays for human MSP that are undergoing 
further development. 
Currently, my hypothesis is that overexpression of MSP by tumor cells not 
only leads to an increase in pro-MSP, but also the cleaved activated MSP due to 
concomitant expression of high levels of matriptase. Although perhaps the crucial 
measurement concerns the cleaved, activated form of MSP, unfortunately neither 
IHC nor ELISA methods are currently capable of specifically detecting active 
MSP. It may be possible to design an antibody targeting the cleavage site within 
MSP resulting in the specific detection of pro-MSP.  Serum concentrations of 
MSP would then be measured using an antibody specific for pro-MSP and an 
antibody which detects both pro- and active MSP. Active MSP concentrations 
may then be calculated as total MSP subtracted from pro-MSP concentrations. 
Another possibility would be to perform Western blot analysis on serum samples 
(under denaturing conditions) for semiquantitative measurements of pro- versus 
active MSP. While it is clear that the techniques for determining the concentration 
of active MSP require further development, doing so would allow important 
questions to be answered, especially for determining whether MSP could serve 
as a valuable biomarker predicting response to Ron inhibitors. Because the 
MSP/Ron pathway is not dependent on the RANKL pathway, MSP expression 
levels may also predict a failed response to RANKL antagonism. My data predict 
that patients with high levels of MSP may be less responsive to denosumab; Ron 







5.4 Markers of bone turnover and their use in clinical trials 
Several factors can be involved in determining bone quality, including 
bone density and qualitative determinants of bone strength such as the rate of 
bone turnover, the extent of trabecular connectivity, cortical and periosteal bone 
size, and skeletal morphometry (Wheater 2013). Bone is a metabolically active 
organ and is constantly being repaired and remodeled throughout an individual’s 
lifetime. In recent years, cellular components of the bone matrix have been 
identified and categorized as markers of either bone formation or bone 
resorption. Markers of bone formation are either by-products of active 
osteoblasts or osteoblastic enzymes. The most widely used markers of bone 
formation include bone specific alkaline phosphatase (BSAP), osteocalcin, and 
the amino-terminal propeptide of type I collagen (P1NP) (Vasikaran 2011). The 
majority of bone resorption markers are degradation products of bone collagen 
such as carboxy-terminal and amino-terminal cross-linked telopeptides of type I 
collagen (CTx and NTx, respectively). Another marker of bone degradation is 
tartrate-resistant acid phosphatase (TRAF5b), an osteoclast-specific enzyme 
produced by actively resorbing osteoclasts (Vasikaran 2011). Although widely 
used in research, the diagnostic importance of bone turnover markers remains to 
be validated, in part due to their analytical and biological variability. Despite this 
variability, tests to evaluate these biomarkers of bone turnover are often included 
in clinical trials involving antiresorptive therapies. These tests are thought to be 
useful in monitoring a patient’s response to an antiresorptive treatment, 





remodeling abnormalities can be evaluated by means such as bone scintigraphy 
or magnetic resonance imaging (Wheater 2013). It is important to realize, 
however, that these markers of bone turnover do not themselves control skeletal 
metabolism and are not disease specific – they reflect the entire skeletal dynamic 
regardless of the underlying cause. Because of this, these markers can be 
extremely useful in assessing the biologic action, if not the therapeutic efficacy, 
of antiresorptive therapy (Black 2007; Bone 2008). While I have observed 
obvious bone destruction in various models with high MSP expression using 
imaging, I have not yet measured bone turnover markers. Importantly, I have yet 
to demonstrate whether these markers are changed upon treatment with Ron 
inhibitors. The measurement of these markers will become especially important 
in clinical trials involving Ron inhibitors, as it is a noninvasive technique to 
determine preliminary efficacy as well as dose selection. Measurements of bone 
remodeling are currently determined by performing a bone scan involving 
technetium and single photon emission computed tomography. While this type of 
imaging is less sensitive, and requires longer time to evaluation, it is still 
considered the gold standard for measuring bone abnormalities (Wheater 2013). 
However, new imaging modalities have been and are being developed to 
accurately image and potentially measure bone turnover. One of the new 
imaging techniques involves a combination positron emission 
tomography/computed tomography (PET/CT) scan using the radioisotope sodium 
fluoride-18 (Na/F18). The fluoride ion is incorporated into metabolically active 





(Schirrmeister 1999; Schirrmeister 1999). What is less clear, however, is whether 
these imaging technologies (either standard of care or the newly developed 
technology) are equally sensitive for detecting both osteoblastic and osteolytic 
lesions. This is a crucial point, as bone lesions in breast cancer are primarily 
osteolytic and Ron inhibitors are would primarily function to block osteolysis, not 
osteoblastic activity. I am now performing experiments in the PyMT mouse model 
utilizing tests to measure markers of bone turnover and Na/F18 PET/CT imaging 
as preclinical experiments to aid in the design of future clinical trials. 
 
5.5 ASLAN002 phase II clinical trial 
We are currently in the process of designing a randomized phase II clinical 
trial in collaboration with ASLAN pharmaceuticals and Bristol-Meyers Squibb 
(see Appendix and Figure 5.1). This trial will involve breast cancer patients with 
bone metastases whose bone lesions are not responsive to bisphosphonate 
therapy. It will likely include an active comparator, though whether this should be 
zoledronic acid or denosumab has yet to be determined. The primary outcome 
measure will be the percent change in the bone turnover marker β-CTx from 
baseline to week 8. This time point may be extended depending upon results at 
week 8, or on results from any Phase I trial data involving ASLAN002 in 
combination with standard of care chemotherapy, if applicable. Secondary 
outcome measures are to be a change in median time to first on-study SRE, and 
the percentage of participants experiencing on-study SREs. Exploratory outcome 





tissue, measurement of MSP in the serum, and progression-free survival. 
Subgroups will be specified based on the expression of MSP and Ron in primary 
tumor samples and breast cancer subtype using standard methods of analysis. 
Analysis of MSP expression will be used to determine whether MSP expression 
(or levels of expression) can predict a response to ASLAN002. Determining Ron 
expression will aid in the evaluation of the effect of ASLAN002 on the primary 
tumor or visceral metastases, if any, and whether this correlates with Ron 
expression. It is possible that ASLAN002 will have an effect on the primary tumor 
independently of Ron expression, possibly due to inhibition of another tyrosine 
kinase target such as Met or Axl. Analysis of collected samples for these kinases 
would help to determine this. Analysis of breast cancer subtype may give 
information regarding subtype specific response to Ron inhibitors, and allow the 
study of MSP-dependent bone destruction among the breast cancer subtypes. 
Use of a CT scan may allow us to determine whether ASLAN002 has an effect 
on visceral metastases based on tumor response rate measurements. Finally, 
analysis of bone turnover markers will allow us to correlate Ron inhibition with the 
inhibition of tumor-induced bone destruction. The questions answered in this trial 
will allow us to further understand the mechanism of MSP-dependent bone 
destruction and, more importantly, determine whether Ron inhibitors represent a 
safe and effective therapy against bone destruction due to breast cancer bone 
metastases. This knowledge will also be critical in determining the potential uses 
of Ron inhibitors not only in breast cancer, but also in other bone metastatic 





5.6 MSP and Ron in multiple myeloma 
Another cancer type where Ron inhibitors could prove useful is multiple 
myeloma. Multiple myeloma (MM) is a neoplastic plasma-cell disorder that is 
characterized by clonal proliferation of malignant plasma cells in the bone 
marrow microenvironment. It is the second most common hematopoietic 
malignancy, with an incidence of around 20,000 per year in the United States 
(Kuehl and Bergsagel 2012). Symptoms of MM primarily include end-organ 
damage such as lytic bone lesions, anemia, immunodeficiency, and decreased 
renal function. Myeloma is thought to arise most commonly from a premalignant 
tumor called monoclonal gammopathy of undetermined significance (MGUS), 
which then progresses to smoldering myeloma and finally to symptomatic 
myeloma. MGUS is distinguished from MM by having less intramedullary tumor 
cell content (<10%). Smoldering myeloma has a stable intramedullary tumor cell 
content (>10%) but no complications commonly associated with MM. Progression 
of smoldering myeloma to malignant myeloma is associated with increasingly 
severe secondary features (lytic bone lesions, anemia) (Kuehl and Bergsagel 
2002). Osteolytic lesions develop in approximately 80% of patients with newly 
diagnosed disease, and around 60% of patients report bone pain (Kyle 2003). 
Lytic lesions in MM develop due to increased osteoclast activity and decreased 
osteoblast activity. The mechanism of decreased osteoblast activity is not fully 
understood but is thought to involve inhibition of the Wnt pathway, which leads to 
the suppression of osteoblasts. Bone marrow biopsies from MM patients show a 





also demonstrate a decrease in trabecular thickness and low calcification rate 
with decreased osteoblast numbers indicating a disruption of the balance of bone 
remodeling (Raje and Roodman 2011). 
 There are many cytokines and growth factors known to activate 
osteoclasts in MM. These factors are generated by the mutual interactions of 
tumor and bone marrow cells and include IL-6, RANKL, and macrophage 
inflammatory protein 1α (Palumbo and Anderson 2011). Interestingly, the 
development of osteolytic lesions is not limited to a secondary effect of an MM 
tumor. Many components of the microenvironment support the propagation of 
tumor cells and MM is an exquisitely niche-dependent cancer. Several studies 
using bone-targeted agents have suggested that restoring bone homeostasis 
may lead to inhibition of tumor growth. Although osteoblasts secrete MM growth 
factors such as IL-6, they have an overall inhibitory effect on MM proliferation 
(Yaccoby 2006). For example, inhibition of DKK1, and the resulting relief of 
osteoblast inhibition, resulted in reduction of tumor growth primarily as an indirect 
effect via modification of the microenvironment (Fulciniti 2009). Another possible 
mechanism by which the bone niche (particularly osteoblasts) can suppress MM 
is that the osteoblast-derived extracellular matrix component decorin, which 
regulates bone formation and mineralization, induces MM cell apoptosis via p21 
activation, and inhibits osteoclastogenesis (Li 2008). Treatment with zoledronic 
acid also inhibits MM growth, although it is not clear whether this is due to the 
effects of the bisphosphonate on blocking osteoclast activity, bisphosphonates 





direct antimyeloma activity. These questions remain unanswered; trial designs 
always include bisphosphonates as supportive care therapy and data for 
antitumor activity are gathered in a post hoc analysis (Raje and Roodman 2011). 
Although osteoclasts are a critical component in the development of bone 
disease, osteoblasts are also affected in MM and they are known to contribute to 
the development of osteolysis. It is likely that effective therapeutic strategies to 
overcome the detrimental osteolysis that occurs in MM patients will target both 
osteoclasts and osteoblasts, combining bone-anabolic and anticatabolic 
therapies. Novel agents with dual activity on bone remodeling may not only 
prevent osteolytic lesions but will also possibly result in improvement of the bone 
disease. Perhaps more importantly, therapies that restore the balance in bone 
remodeling in MM may also create an unsupportive microenvironment for MM 
tumor growth. 
 Currently, there is very little known about a role for MSP/Ron in MM. Using 
a publically available cancer data set, I found MSP expression to be significantly 
higher in MM tumors compared to normal plasma cells (Figure 4.S7A). This is the 
first evidence suggesting a potential role for MSP in this disease setting and I do 
not yet know whether Ron is also expressed. I have convincingly shown that the 
mechanism of MSP-dependent osteolysis is through osteoclast activation and I 
have also demonstrated that the involvement of osteoblasts is unlikely. I was not 
able to detect Ron protein expression in an osteoblast cell line and osteoblasts in 
vivo do not stain positively for Ron by IHC (Figures 4.S1G and 4.S1H). I have 





activity as measured by mineral apposition rate or bone formation rate (Figures 
4.S1C-F). It is therefore unlikely that inhibition of Ron alone could have the 
desired effect of modifying the activity of both osteoblasts and osteoclasts. 
Inhibition of Ron alone would not affect the production of growth factors 
responsible for fueling tumor growth and suppressing osteoblast activity. 
However, none of the currently available Ron inhibitors target Ron specifically - 
they also target the receptor tyrosine kinase Met (Yao 2013). Met is the receptor 
for hepatocyte growth factor (HGF) and is the only other member of the receptor 
tyrosine kinase family that includes Ron. Ron and Met are structurally very 
similar, with 63% amino acid conservation within the kinase domain and 34% 
overall amino acid identity (Kretschmann 2010). Their ligands, HGF and MSP, 
are also very similar, with 45% identity. They are both glycoproteins that are 
secreted as inactive single-chain peptides and need to be proteolytically cleaved 
to become active. Despite their similarity, however, the ligands and receptors are 
not interchangeable with each other (Kretschmann 2010). 
 
 
5.7 Role of HGF/MET in multiple myeloma 
While little is known about the function of Ron and MSP in MM, there is a 
substantial amount of data indicating an important role for Met and HGF in this 
disease. High levels of both HGF and Met have been observed in MM, allowing 
for autocrine activation. In addition, bone marrow stromal cells produce HGF, 
suggesting paracrine stimulation of MM cells within the bone marrow 





serum and high Met expression by MM tumor cells have both been shown to be 
associated with poor prognosis in MM patients (Kristensen 2013; Rocci 2014). 
HGF stimulation of MM cells promotes proliferation, migration, and survival. 
Additionally, HGF stimulation protects MM cells from apoptosis through RAS 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase 
protein kinase B (PI3K/PKB) signaling (Derksen 2003). The HGF/Met pathway 
has also been shown to play an important role in modifying bone metabolism; 
MET is expressed on osteoclasts and osteoblasts. HGF inhibits bone 
morphogenetic protein (BMP)-induced osteoblastogenesis and maintains human 
mesenchymal stem cells in a proliferative, undifferentiated state (Standal 2007). 
As it is known that MM cells are inhibitory to osteoblasts, and given the high 
expression of HGF in MM cells, HGF is considered to be one potential 
osteoblast-inhibiting factor in multiple myeloma. 
 While the role of HGF in osteoclasts is not entirely clear, it has been 
shown to substitute for M-CSF in RANKL-induced differentiation and increase the 
motility of osteoclasts while having no effect on their resorptive activity 
(Adamopoulos 2006; Gaasch 2006). Additionally, HGF was found in the media of 
human osteoclast-like cells isolated from bone giant cell tumors grown in vitro, 
suggesting the possibility of paracrine signaling to osteoblasts. Because of this 
evidence, HGF has been proposed to act as a coupling factor for osteoclasts and 
osteoblasts (Grano 1996). While an interesting possibility, much of this 





 Given the important role for HGF/Met, and the possible role for MSP/Ron 
in MM, an inhibitor targeting both of these pathways could potentially disrupt 
multiple processes involved in MM growth and development of lytic disease. I 
have shown that inhibition of Ron on osteoclasts can potently block their 
resorption ability both in vitro and in vivo (Figures 4.1B and 4.6A). Inhibition of 
Met in osteoclasts should block their proliferation; however, I have not observed 
a reduction in the proliferation rate in vitro or total osteoclast numbers in vivo 
upon treatment with Ron/Met inhibitors. It is possible that this is the result of the 
lower IC50 for Met vs. Ron in the case of ASLAN002 (Schroeder 2009), but this is 
not likely the case for OSI296 as it is slightly more Met-selective (Steinig 2013). 
The effect of those inhibitors on Met activity in osteoclasts and the outcome of 
Met inhibition will need further study. Inhibition of Met in osteoblasts would be 
predicted to result in their activation, while inhibition of Ron would presumably 
have no effect; I have not been able to detect Ron expression in osteoblasts. I 
did not see an increase in osteoblast activity after treatment with OSI296 or 
ASLAN002. Experiments utilizing osteoclasts or osteoblasts in vitro to test the 
effects of inhibitors which target Ron or Met preferentially, or inhibitors which 
target both of these receptors equally, will help to answer questions regarding the 
effects that these drugs have in these cell types. Despite the lack of evidence for 
Met inhibition in my in vivo experiments, it is important to note that the models I 
used to test these inhibitors do not express high levels of HGF, and so Met may 
not be activated in these models. Utilizing mouse models of MM which express 





in vivo. Co-culture in vitro experiments may also be required, given the possible 
role of HGF in paracrine signaling events. Mouse models of MM will help to 
determine whether MSP or Ron are expressed, and the effect that their 
expression have on MM tumor growth and osteolysis. Information from patient 
tumors could be very informative as well. It would be interesting to determine 
what percentage of MM patient tumors express MSP, and whether MSP 
expression correlates with disease progression or severity of osteolysis. 
Determining expression levels of MSP in patient tumors, and potentially in patient 
sera, will also help to validate the use of MSP overexpression in mouse models 
of multiple myeloma. Performing these studies in MM will expand our 
understanding of the role of MSP/Ron in different cancers, and potentially 
increase the use for Ron/Met inhibitors for treatment. In addition, studying 
Ron/Met specific or dual inhibitors in models of MM will aid in understanding the 
interplay of these two pathways and the roles they each have in bone 
remodeling. 
 
5.8 Role of MSP/Ron in immune-mediated bone loss 
A relationship between inflammation and bone disease has long been 
established in many clinical and experimental models (Spector 1993; Gough 
1994; Bernstein 2000; Bultink 2005). It is now understood that the immune 
system has varied effects on the delicate balance of bone resorption and bone 
formation, both in physiological and pathological settings (Hardy and Cooper 





systemic bone loss and the mechanisms involved are complex and interrelated. 
These diseases include inflammatory joint disease, inflammatory bowel disease, 
lung inflammation, renal disease, and diseases affecting nerve and muscle 
(Hardy and Cooper 2009). While the mechanisms underlying bone loss in these 
diseases are similar in some respects to one another, they also have distinct 
components. In addition, specific treatments for these conditions can contribute 
to the bone loss associated with these diseases. Nevertheless, it is clear that 
osteoclast activation plays a crucial role in inflammation-associated bone loss. 
 Rheumatoid arthritis (RA) represents a common example of a systemic 
inflammatory process, which leads to significant changes in bone metabolism. 
This inflammatory process targets the articular cartilage, bone at the joint 
margins, as well as periarticular and subchondral bone (Goldring 2004). During 
the development of RA, the normally thin synovial lining, composed of fibroblast- 
and macrophage-like cells, undergoes intense proliferation to form a hyperplastic 
structure called the pannus. The pannus invades the joint space and destroys the 
cartilage through inflammatory cytokines, which directly affect chondrocytes, and 
by degradative enzymes liberated from synoviocytes (Jones 2011; Noss 2008). 
As the pannus tissue encroaches on periarticular bone, erosion occurs through 
inflammation-induced osteoclast differentiation and activation (Jones 2011; 
Takayangi 2009). Various inflammatory mediators expressed within the synovial 
tissues have the ability to modify the bone remodeling process and promote bone 
resorption by direct activation of osteoclasts within the pannus. Macrophages 





of macrophages present at the bone-synovial interface correlates with the degree 
of bone damage. Additionally, synovial macrophages are thought to serve as the 
progenitors for osteoclasts within the synovium, though other cell types may be 
capable of transdifferentiating as well (Takayanagi 2009). 
 Osteoarthritis (OA) is similar to RA in that it results in pathological 
changes in the components of the diarthroidal joint. OA is often characterized as 
a disease of articular cartilage; however, it is becoming clear that changes in the 
subchondral bone also play a key role in structural destruction of the joint (Suri 
2012). Unlike RA, the pathological changes occurring within the joint in OA are 
thought to occur first, with the associated inflammation acting as a secondary 
response to the dysfunctional cells and tissues within the joint. This inflammatory 
response tends to be milder than in RA, although in some patients, the amount of 
inflammation in OA becomes indistinguishable from that of RA. Similar to RA, 
where the initial cause of inflammation is unknown, the initial cause of cellular 
dysfunction in OA is also currently unknown. 
 
5.9 MSP/Ron in inflammation 
 Ron acts as a crucial regulator of inflammation by inhibiting classical 
macrophage activation and promoting alternative activation of macrophages. The 
promotion of alternative macrophages results in the resolution of inflammation 
and tissue repair (Kretschmann 2010; Wang 2013). Expression of Ron is found 
on multiple types of resident macrophages, including alveolar macrophages, 





Brunelleschi 2001; Suzuki 2008). Experiments have demonstrated the 
importance of the MSP/Ron pathway in protection against Gram-positive 
bacteria. Ron TK-/- mice challenged with Listeria monocytogenes showed an 
increase in bacterial burden and susceptibility to infection. These results suggest 
that a lack of Ron results in the inability of macrophages to efficiently eliminate 
intracellular bacteria (Lutz 2003). In models of lung injury, Ron proved to be 
essential for protection from unregulated inflammation; Ron TK-/- mice displayed 
increased lung injury due to their inability to downregulate inflammatory cytokines 
(Lentsch 2007; McDowell 2002). MSP/Ron have also been shown to interact with 
the acquired immune system, at least in the cancer setting, by suppressing the 
recruitment of activated CD8+ cytotoxic T cells to the site of metastatic disease 
(Eyob 2013). However, it is still unclear whether this is due to MSP/Ron signaling 
in macrophages and the mechanism by which this occurs has yet to be 
elucidated. It is also not clear whether Ron activation is capable of suppressing 
CD8+ T cell recruitment in other disease settings. 
 
5.10 MSP/Ron in inflammatory arthritis 
Given the role of the MSP/Ron pathway in osteoclast activation and 
inflammation in various settings; it is plausible that this pathway may also 
function in inflammatory diseases. In types of arthritis associated with bone 
destruction, such as RA and OA, macrophages within the synovial lining play a 
key role in the inflammatory process. Interestingly, MSP has been shown to be 





evidence suggests that there may be a source of MSP produced within the 
inflamed joint, though it is not known whether this source is from macrophage-
like or fibroblast-like cells, both of which compose the synovial lining. The 
accumulation of macrophages could potentially provide a source of matriptase 
that could cleave and activate pro-MSP (Bhatt 2007). In addition, matriptase is 
highly expressed in the synovial cartilage of OA patients compared to normal 
cartilage, where it acts to stimulate collagenolysis during pathogenesis (Milner 
2010). Activation of MSP could then cause Ron activation in osteoclasts located 
within the pannus, thereby leading to bone resorption. Finally, MSP was 
identified as a potential biomarker in the plasma of patients with OA whose 
plasma levels correlated with disease progression (Fukuda 2012). The presence 
of synovial inflammation often associated with OA is believed to be a secondary 
phenomenon related to the destruction of cartilage and release of breakdown 
products into the synovial fluid. However, the changes that occur in the synovium 
are often indistinguishable from that of patients with RA (Pelletier 2001). It would 
be interesting to determine whether MSP is also expressed in the joints of RA 
patients and whether MSP plasma concentrations correlate with RA disease 
progression. In addition, while it is likely, matriptase expression has yet to be 
demonstrated in cartilage from RA patients. Thus, Ron inhibitors may also be 








5.11 Chondrocytes in inflammatory arthritis 
Chondrocytes are another important cell type involved in inflammatory 
arthritis. Under normal physiologic conditions, these cells express various 
proteolytic enzymes such as matrix metalloproteinases (MMPs), which mediate 
the very low levels of matrix turnover responsible for cartilage remodeling (Van 
Osch 2009). In pathological conditions such as RA or OA, chondrocytes increase 
the production of these enzymes considerably, resulting in aberrant cartilage 
destruction (Pelletier 2001; Aigner 2002). I have found for the first time that Ron 
is expressed in chondrocytes (Figure 4.S1G); however, its function in these cells 
is still completely unknown. One important factor produced at high levels by 
chondrocytes during pathogenesis is MMP13 (Chiu 2007). MMP13 (also known 
as collagenase 3) is the most potent of the enzymes responsible for the 
degradation of type II collagen, the primary collagen type in cartilage (Li 2011; 
Troeberg 2012; Martel-Pelletier 1996). While it is not known whether Ron 
activation in chondrocytes leads to MMP13 expression, I have found that PyMT 
tumor cells overexpressing MSP have 2 to 3 fold higher MMP13 expression 
compared to PyMT control tumors (unpublished data). It would be very 
interesting to determine whether MSP stimulation of Ron in chondrocytes leads 
to MMP13 production, which could implicate a role for this pathway not only in 
bone destruction, but also in the cartilage destruction that occurs in inflammatory 
arthritis. Similar to MMP13, chondrocytes also produce high levels of the 
inflammatory mediator IL-6 (Pelletier 2001), another cytokine produced 





possible that Ron activation in chondrocytes could lead to the production of IL-6, 
which has the potential to not only contribute to the overall inflammatory process 
but to bone destruction as well; IL-6 is capable of inducing osteoclastogenesis 
(Kudo 2003). Using the chondrocyte-specific Cre expressing mouse (Col2a1-
Cre) along with the osteoclast-specific Cre mouse (Cathepsin K-Cre) that we now 
have in the lab could be useful in differentiating between the effects of Ron in 
osteoclasts and the potential role of Ron in the chondrocytes in various disease 
models. 
 While the role of the MSP/Ron pathway in RA and/or OA is an interesting 
possibility, there are many questions that need to be investigated. The levels of 
MSP protein present within the arthritic synovial fluid of both RA and OA patients 
needs to be determined. More importantly, the ratio of pro-MSP compared to 
cleaved, activated MSP needs to be determined, as arthritic joints may have 
more activated MSP due to high matriptase. If MSP is indeed expressed by cells 
within the synovial lining, these cells need to be identified. This would be 
particularly interesting as the production of systemic MSP is primarily in the liver. 
The role of Ron in these diseases also needs to be elucidated. There are many 
models used to study both RA and OA. If Ron has an important role in osteoclast 
activation in these diseased settings, it is very likely that the Ron TK-/- mouse 
would be resistant to arthritis-induced bone loss. It would also be interesting to 
test the efficacy of Ron inhibitors in this setting. Ron inhibition could block not 
only bone destruction, but may potentially also block some of the inflammation 





IL-6 and TNFα has not been tested; it would be interesting to see if treatment 
could reduce resorption, even in the absence of MSP. Factors capable of 
activating osteoclasts are often analyzed together. It would be interesting to 
determine which pathways are driving the bone destruction in RA/OA. Whether 
MSP/Ron have a role in macrophage function within the setting of RA and OA 
also needs to be determined. Due to existing evidence describing important roles 
in immune response, specifically in macrophages, it is likely that there is a role; 
however, the function of MSP/Ron within the immune system may be context 
dependent. While its initial role is to stimulate the immune system, its most 
important role is thought to be in shutting down the immune response once 
infection or injury has been resolved. It is possible that in RA/OA the MSP/Ron 
pathway is expressed in an attempt to control the rampant inflammation 
occurring. However, the expression of the pathway may inadvertently lead to 
bone destruction, and possibly increased cartilage destruction, which only 
enhances the inflammatory response in these diseases. 
 In conclusion, I have demonstrated that MSP/Ron functions as an 
important pathway not only in bone biology, but also in cancer-induced bone 
destruction. I have shown that MSP/Ron are capable of regulating many 
important functions within the osteoclast and may be an important player in many 
pathological diseases that influence bone remodeling. Finally, I have 
demonstrated that Ron inhibitors successfully block tumor-induced bone 
destruction and osteoporotic bone loss. Future work will define Ron signaling in 





help to determine the applicability of the Ron pathway in other cancers, 
pathologic bone diseases, and the feasibility of using these inhibitors in various 
clinical applications. 
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PHASE II RANDOMIZED CLINICAL TRIAL OF ASLAN002  


















The most common site of metastasis in breast cancer patients is bone, 
which occurs in about 80% of patients with advanced disease. A characteristic 
feature of these metastases is their osteolytic nature, which causes remarkable 
bone loss, fractures, severe pain, hypercalcemia, and other detrimental effects. 
The Macrophage Stimulating Protein (MSP), its receptor RON, and the protease 
that activates MSP, MT-SP1, are highly expressed in up to 20% of breast cancer 
patients. These patients exhibit increased metastasis to lung, liver, brain, and 
bone, with bone being the most frequent site of metastasis. Treatment with a 
RON inhibitor, ASLAN002, successfully inhibits the development and progression 
of osteolytic lesions caused by breast cancer cells in an animal model. In 
addition, ASLAN002 is currently in a phase I clinical trial and has demonstrated a 
relatively safe and reversible toxicity profile which can be easily monitored 
(NCT01721148). Taken together, these data suggest that Ron could be a 
potentially useful therapeutic target in breast cancer metastasis to bone for the 
treatment of osteolytic lesions, particularly when the patients’ tumor expresses 
the RON ligand, MSP. 
There is a great need for new therapies for metastatic cancers which have 
progressed on or are unresponsive to current therapy. There are no approved 
RON targeted agents in standard clinical use. In the population of subjects with 
advanced breast cancer metastatic to bone whose tumors are unresponsive to 





a clinical study, the potential for benefit from ASLAN002 outweighs the potential 
risks for toxicity. 
 
A.2 Primary hypothesis 
Our central hypothesis is that patients with metastatic breast cancer 
unresponsive to bisphosphonate therapy who are treated with ASLAN002 have 
lower markers of bone resorption compared to placebo. 
 
A.3 Purpose 
The purpose of this study is to identify the safety and efficacy of 
ASLAN002 in a randomized, phase II study of subjects with advanced breast 
cancer which has metastasized to bone. 
 
A.4 Treatment arms and justification 
Placebo versus ASLAN002 (administered orally) 
- Justification: Patients eligible to enroll in the trial have failed the FDA-
approved standard-of-care bisphosphonates and placebo is therefore 
justified 
- Standard of care medications for metastatic disease (other than bone) 









A.5 Primary and secondary endpoints 
 
 
A.5.1 Primary outcome measures 
 Percent change in β–CTX from baseline to week 8 
 
A.5.2 Secondary outcome measures 
 Change in F18/Na PET SUV signal from baseline to week 8 
 Overall response rate in visceral metastases determined by RECIST 
criteria at week 8 
 Overall safety profile of ASLAN002 (adverse events, labs) at week 8 
 Bone pain (use of analgesic medications) at week 8 
 Percentage of participants experiencing on-study skeletal related event(s) 
(SREs) at week 8 
 Median time to first on-study SRE 
Skeletal Related Events (SREs) are defined as a: 
 Pathologic bone fracture such as nonvertebral and vertebral compression 
fractures 
 Spinal cord compression identified by clinical exam documented by X-ray 
evidence 
 Surgery to bone both curative and prophylactic 





 Hypercalcemia of malignancy, defined as a corrected serum calcium > 12 
mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is 
symptomatic and which requires active treatment other than rehydration 
 
A.5.3 Exploratory outcome measures 
 To explore biomarkers that are potentially predictive of biological response 
to ASLAN002, including IHC markers for MSP/Ron signaling pathway 
activity in tumor tissue and serum 
 Progression-free survival 
 
A.5.4 Rationale for selection of outcome measures 
Use of percent change in markers of bone turnover as a surrogate 
outcome is appropriate for the following reasons (Brown 2003; Coleman 2005; 
Fizazi 2009; Leeming 2006; Lein 2007; Lipton 2007; Piedra 2013): 
 The continuous variable of bone turnover assays allows for maximum 
power in the study in addition to providing meaningful data in a short time 
period 
 Changes in biochemical markers of bone turnover correlate significantly 
with a change in fracture risk (SRE) and predict long-term response to 
bone therapy 






 FDA approval of bone targeted therapeutics is given after evidence is 
provided by phase III trials using the surrogate outcome of median time to 
first on-study SRE and/or total number of on-study SREs. Overall survival 
and progression-free survival are often included as exploratory end points 
and are usually reserved for phase III trials with a longer follow-up time 
period. 
A.6 Study design 
 
 
A.6.1 Design summary 
 
This is a randomized phase II study of ASLAN002 administered orally to 
subjects with advanced or metastatic breast cancer for whom the standard of 
care is either ineffective or inappropriate. Subjects will be enrolled in cohorts of 
92 patients to either placebo or ASLAN002 on a once daily schedule with a dose 
of 600 mg for 8 weeks.  
 
A.6.2 Duration of study 
The intervention and follow-up is expected to last at least 12 weeks with 
treatment lasting 8 weeks and follow-up lasting at least 4 weeks. Subjects may 
discontinue from treatment because of disease progression, unacceptable 
toxicity, or at the subject’s request. Subjects who withdraw from treatment before 
8 weeks will be asked to participate in a final visit 4 weeks after discontinuation of 







A.6.3 Subgroup specification 
 Expression of Ron in primary tumor samples (immunohistochemical 
staining) (positive/negative) 
 Expression of MSP in primary tumor samples (immunohistochemical 
staining) (positive/negative) 
 Breast cancer subtype (ER+, HER2+, and triple negative) 
 
A.7 Recruitment 
A.7.1 Eligibility inclusion criteria 
 Female patients ≥ 18 years of age 
 Able and willing to give written informed consent  
 Histologically confirmed Stage IV breast cancer with at least one bone 
metastasis radiologically confirmed (including radiography, computed 
tomography (CT), PET scan, PET/CT scan, magnetic resonance imaging, 
bone scan, or skeletal survey) that have either progressed on standard 
therapy or for whom standard therapy is not known. 
 Life expectancy of ≥ 3 months 
 Prior anticancer treatments are permitted (i.e., chemotherapy, 
radiotherapy, hormonal, or immunotherapy) 
 Prior bone therapies will be permitted. Three weeks must have elapsed 
between prior bone therapy and the initiation of the study therapy 
 Patients unresponsive to bone therapy as indicated by levels of serum β-





 Archived primary tumor tissue available in paraffin-embedded blocks or 
slides 
 Ability to comply with visits/procedures required by the protocol 
 
A.7.2 Eligibility exclusion criteria 
 Patients unable to swallow or take anything orally 
 Patients with a serum creatinine > 3 mg/dL (265 µmol/L) or calculated 
(Cockcroft-Gault formula) creatinine clearance (CrCl) < 30 mL/min CrCl = 
({[140-age (years)] x weight (kg)}/ [72 x serum creatinine (mg/dL)]) x 0.85 
 Patients with corrected serum calcium ≤ 8.0 mg/dL and > 11.6 mg/dL 
 Women who are pregnant  (with a positive pregnancy test prior to study 
entry) or lactating patients 
  Women of childbearing potential unwilling or unable to use effective 
methods of birth control (e.g., oral contraceptives or implants, IUD, vaginal 
diaphragm or sponge, or condom with spermacide) 
 Patients treated with systemic investigational drug(s) and/or device(s) 
within the past 30 days or topical investigational drugs within the past 7 
days. 
 Patients currently receiving bisphosphonates. Bisphosphonates must have 
been discontinued ≥ 3 weeks prior to randomization 
 Patients currently receiving Denosumab. Denosumab must have been 
discontinued ≥ 2 weeks prior to randomization 
 Patients currently treated with radiotherapy. Radiotherapy must be 





 Patients currently treated with any drugs known to affect the skeleton 
(e.g., calcitonin, mithramycin, systemic glucocorticoids, or gallium nitrate) 
within 2 weeks prior to randomization 
 History of diseases with influence on bone metabolism, such as Paget’s 
disease, osteogenesis imperfecta, and primary or secondary 
hyperthyroidism within 12 months prior to study entry 
 Patients with known symptomatic brain metastasis. Subjects with 
controlled brain metastasis (no radiographic progression at least 4 weeks 
following radiation and/or surgical treatment and no neurological signs or 
symptoms) will be allowed 
 History of allergy to ASLAN002 (BMS-777607) or chemically related 
compounds 
 
A.7.3 Discontinuation of subjects from treatment 
Subjects must discontinue study treatment for any of the following reasons: 
 Withdrawal of informed consent (subject’s decision to withdraw for any 
reason) 
 Any clinical adverse event, laboratory abnormality or intercurrent illness 
which, in the opinion of the investigator, indicates that continued 
participation in the study is not in the best interest of the subject 
 Disease progression as determined by RECIST criteria 
All patients who discontinue study treatment should comply with protocol 







Blood is drawn and urine collected at specified time points for bone 
marker analysis and labs (fasting morning sample). Blood samples will be 
collected on all subjects at screening, prior to dosing on Day 1, and at time points 
indicated. Samples taken during screening will be evaluated according to 
eligibility criteria for laboratory values. In addition, levels of β-CTx in the serum 
will be measured to determine whether the patient is unresponsive to prior bone 
therapies (≥ 400 pg/mL). 
 Required to take oral placebo or ASLAN002 daily 
 Imaging for a Na/F18 PET/CT scan and X-ray 
 
A.8.1 Data and specimens to be collected 
 Levels of bone markers for bone turnover in patient serum 
 PET/CT signal for tumor growth and bone turnover 
 Laboratory test assessments (hematology, serum chemistry, urinalysis, 
pregnancy test) 
 Tissue sections of the primary tumor (archived) 
 Patient demographics and baseline characteristics 
 Vital signs 
 Physical examination and measurements (height, weight and ECOG 
performance status) 
 Patient medical history 





A.8.2 Criteria for evaluation 
 Safety outcome measures: All patients who receive treatment will be 
evaluated for safety. Safety assessments will be based on medical review 
of adverse event reports and the results of vital sign measurements, 
physical examinations, and clinical laboratory tests. Toxicity will be 
evaluated according to the NCI Common Terminology Criteria for Adverse 
Events (CTCAE v. 3.0). 
 Efficacy measures: Determine metastatic tumor response [Time Frame: 
From baseline to 8 weeks (+/- 7 days)]. Tumor response will be 
determined for all subjects with measurable disease as defined by the 
RECIST criteria. Computed tomography assessments will be made every 
4 weeks or more frequently if indicated. Changes from baseline tumor size 
determined by RECIST criteria and the percent change from baseline in 
the sum of the longest diameters in target lesions will be determined. A 
maximum of 5 lesions per organ and 10 lesions in total should be 
identified as target lesions to be measured. The target lesions should be 
representative of all involved organs. The baseline sum of the longest 
diameter of target lesions will be used as the reference by which to 
characterize the objective tumor response. Tumor response will be 
determined as follows: 






o Partial Response (PR): Decrease, relative to baseline, of 30% or 
greater in the sum of the longest diameter of all target lesions. 
Additionally, patients must not meet the criteria for progressive 
disease. 
o Stable Disease (SD): Failure to meet criteria for complete or partial 
response, in the absence of progressive disease. 
o Progressive Disease (PD): At least 20% increase in the sum of the 
longest diameter of all target lesions or the appearance of any new 
lesions. 
 Progression-free survival (PFS) will be defined as the time between the 
first dose of study therapy and the date of progression or death. A subject 
who dies without reported prior progression will be considered to have 
progressed on the date of death. For those who remain alive and have not 
progressed, PFS will be censored on the date of last tumor assessment. 
Assessment of the Eastern Cooperative Oncology Group (ECOG) 
Performance Score [Time Frame: From baseline to 8 weeks]. ECOG 
Performance Score has 4 grades. 0 = Fully active, able to carry out all 
predisease activities; 1 = Restricted in strenuous activity but ambulatory 
and able to carry out work of light or sedentary nature; 2 = Ambulatory and 
capable of all self-care but unable to carry out work activities. Active about 
50% of waking hours; 3= Capable of limited self-care, confined to 





cannot carry on self-care. Totally confined to bed/chair. Outcome will be 
summarized as median score for participants at baseline and at 8 weeks. 
 Bone turnover will be assessed by measuring the levels of serum beta-
CTX, TRAP-5b, P1NP, and BSAP [Time Frame: From baseline to 8 weeks 
(+/- 2 days)]. Outcome is given as percent change from baseline to 8 
weeks. Additional measures of bone lesion activity will be assessed by 
Na/F18 positron emission tomography (Na/F18 PET)[Time Frame: From 
baseline to 8 weeks]. Outcome is given as change from baseline or 
standardized uptake value (SUV) of target lesions. SUV is quantified 
according to standardized uptake value representing a region of interest 
corrected for the injected activity and for patient weight or lean body mass. 
 Bone pain will be measured as the use of analgesic medications 
according to the Analgesic Score Scale [Time Frame: From baseline to 8 
weeks]. The outcome is given as the median score for the participants at 
baseline and 8 weeks of treatment. 
The analgesic score used for this study is modified from the Radiation 
Therapy Oncology Group (RTOG) analgesic score scale. The scale 
represents type of medication administered from 0 to 4 where  0 = None 
1. = Minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, 
etc.) 
2. = Tranquilizers, antidepressents, muscle relaxants, and steroids 
3. = Mild narcotics (oxycodone, meperidine, codeine, etc.) 





 Pharmacogenomic/predictive measures: MSP expression, RON 
expression, and breast cancer subtype are the potential predictive 
biomarkers. Tumor material from all subjects will be evaluated during 
screening to determine the presence of these proteins or the proteins 
which define each breast cancer subtype (Estrogen Receptor (ER), 
Progesterone Receptor (PR), and Human Epidermal Growth Factor 
Receptor 2 (HER2)) performed by immunohistochemistry (IHC) and 
described by both percent positivity and overall strength of stain (weak, 
moderate, strong). A patient sample will be considered positive for the 
expression of ER, PR, Ron, and/or MSP if ≥ 1% of the tissue is positive by 
IHC, ≤ 1% will be considered negative for the expression of these 
markers. A patient sample will be considered positive for HER2 if the 
sample has an intensity score of ≥3+, ≤2+ will be considered negative for 
HER2 expression. 
 
A.8.3 Expected adherence to protocol/dropout problems,  
and steps taken to handle them 
Study drug compliance is assessed at each in-person study visit by 
comparing the expected versus actual consumption of study medicine. Each 
subject will bring in all remaining study drug in the original bottles to each follow-
up visit. The study coordinator will count and record the number of remaining 
tablets. At each visit, a new supply sufficient to carry the subject until their 





in-person study visits. Episodes of non-adherence will be reviewed twice weekly, 
and a report will be provided to the investigators and DSMB quarterly.  
 
A.8.4 Premature discontinuation of study therapy 
 Participants who prematurely discontinue treatment with the study 
therapy regimen will remain in the study and follow the Schedule of Events. 
Study drug may be prematurely discontinued/ terminated for any participant for 
life-threatening reactions. The study drug may also be prematurely discontinued 
for any participant if the investigator believes that the treatment is no longer in 




  We will employ a double blind study design to reduce the risk of bias.  
Intervention assignments will be carried out via simple blocked randomization 
using a block size of 2, after eligible participants are screened.  A matched 
placebo will be used in the control group.  This placebo will have as close to 
same color, weight, shape, texture, taste, odor and dissolution properties as the 
study medication (ASLAN002 600 mg) as possible. Active drug and placebo will 
be tested for matching closeness by an independent panel of observers.  The 
study drug and matched placebo will be delivered orally and presented in plain 
containers without marks or identifiers other than the codes which will be only 
decipherable with the key.  Each participant will have a unique drug code that will 





be conducted under specific emergent conditions where unblinding is absolutely 
necessary (examples: child ingestion, serious adverse reaction).  
 
 
A.8.6 Randomization scheme and blinding 
With a sample size of 92, we will use simple block randomization, using a 
block size of 2. This will ensure equal numbers in both arms (placebo versus 
active drug). Factors associated with outcome include: histopathologic subtypes, 
receptor status, grading, DNA classification level, and MSP expression level. We 
anticipate at least 10% in each of the above categories. Thus, simple 
randomization would ensure somewhat balanced enrollment of patients with 
various prognostic factors and there is no need for stratification. 
This is a single center study. Randomization will be done after screening, 
on site. A computer generated list will be kept in a password protected encrypted 
computer on site. A back up of the list will be kept on a separate password 
protected encrypted computer. The randomization scheme for the first 20 
subjects is attached. The list is created in Excel, using the rand() command. With 
a block size of 2, there are 2 permutations: A (active drug, placebo), B (placebo, 
active drug). If the random number is < 0.5, we will choose permutation A. If the 
random number is ≥ 0.5, we will choose permutation B. 
 
 
A.8.7 Justification of sample size 
The Power and Sample Size (PS) software (DuPont, Vanderbilt) was used 





sided alpha of 0.05 and a power of 90% across a range of possible clinical 
differences and standard deviations of the response variable, percent change in 
β–CTX from baseline to 8 weeks (Table A.2). Because this is an early phase trial, 
there are very little existing data to inform sample size calculations.  The starting 
points for our inputs were based on estimates of the change in β–CTX in breast 
cancer patients from baseline to week 25 in the phase II trial described by Fizazi 
and colleagues.  In this study, the median (IQR) percent change in serum CTX 
from baseline to 25 weeks was 34.6% (22.3%) for breast cancer patients 
receiving IV bisphosphonates (3). 
The final sample size was chosen based on an assumed detectable 
difference of 15% and a standard deviation of 20%, resulting in an estimated 76 
required patients total (3).  In order to account for possible dropouts, the sample 
size was inflated by 20% to arrive at a final total sample size of 92 patients, with 
equal allocation of 46 patients each to the placebo and active treatment arms. 
As the DSMB will only review safety aspects of the trial, no interim efficacy 
analyses are planned and therefore no adjustments were made to the overall 
alpha for the trial. 
 
A.8.8 Data analysis and collection techniques 
Data will be collected by trained study nurses and clinicians using 
structured data collection instruments.  Abstracted data will be double-entered 
into a secure research database such as REDCap.  All discrepancies will be 





placebo and to investigational treatment will be compared using two-sample t-
tests for normally distributed continuous variables, Wilcoxon rank-sum tests for 
non-normally distributed continuous variables, and with chi-square and Fisher’s 
exact tests, as appropriate, for categorical variables.  Additional descriptive 
analyses will be performed comparing patients who were and were not 
randomized, as well as patients who remained on-study to those who were lost to 
follow-up, if necessary. 
 
A.8.9 Primary analysis 
The primary endpoint and some secondary endpoints will be assessed at 
8 weeks for all study patients.  As there will be no variability in follow-up time, 
these endpoints will be evaluated using simple two-sample t-tests and chi-
squared tests. These analyses will be conducted in accordance with the 
intention-to-treat principle.  Secondary analyses will evaluate the per-protocol 
population.  The time to first on-study SRE will be evaluated using Kaplan-Meier 
product-limit survival methods and Cox proportional hazards, if necessary based 
on the performance of the randomization scheme.  An extended Cox model will 
be used to account for deaths within a competing risks framework.  Missing data 
will be handled using multiple imputation under the assumption that values are 
missing at random (MAR).   
Subgroup analyses will be performed to evaluate efficacy in patients with 





without MSP expression in their primary tumor sample, and by breast cancer 
subtype (ER+, HER2+, triple negative). 
 
 
 A.8.10 Interim monitoring plan  
The Data and Safety Monitoring Board (DSMB) will review safety data 
quarterly during planned DSMB Data Review Meetings. Data for the planned 
safety reviews will include, at a minimum, a listing of all reported Adverse Events 
and Serious Adverse Events. The DSMB will be informed of an Expedited Safety 
Report in a timely manner. 
In addition to the prescheduled data reviews and planned safety 
monitoring, the DSMB may be called upon for ad hoc reviews. The DSMB will 
review any event that potentially impacts safety at the request of the protocol 
investigator. After careful review of the data, the DSMB will make 
recommendations regarding study conduct and/or continuation. 
 
 
A.8.11 Temporary halt for emergency safety review 
A temporary halt in enrollment will be implemented if an ad hoc DSMB 
safety review is required. In the event that the study temporarily halts enrollment, 
no new subjects will be consented or start on therapy, and subjects already on 
study therapy will continue on therapy unless they are the focus of the DSMB 
review. Subjects in the screening phase of the study may continue to undergo 





deferred. Randomization will not occur until the DSMB review is complete. The 
health authorities will be notified of any halt in enrollment. 
 
A.9 Definitions 
A.9.1 Adverse event (AE) 
An adverse event (AE) is defined as any untoward or unfavorable medical 
occurrence associated with the use of a drug in humans, whether or not 
considered drug related. An adverse event may include any unfavorable or 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of an investigational product. 
 
A.9.2 Suspected adverse reaction (SAR) 
A suspected adverse reaction (SAR) is any adverse event for which there 
is a reasonable possibility that the investigational drug caused the adverse event. 
For the purposes of safety reporting, ‘reasonable possibility’ means there is 
evidence to suggest a causal relationship between the drug and the adverse 
event. A suspected adverse reaction implies a lesser degree of certainty about 
causality than adverse reaction, which means any adverse event caused by a 
drug. 
 
A.9.3 Unexpected adverse event 
An adverse event or suspected adverse reaction is considered 
“unexpected” if it is not listed in the investigator brochure or is not listed at the 





not required or available, is not consistent with the risk information described in 
the general investigational plan. “Unexpected” also refers to adverse events or 
suspected adverse reactions that are mentioned in the investigator brochure as 
occurring with a class of drugs or as anticipated from the pharmacological 
properties of the drug, but are not specifically mentioned as occurring with the 
particular drug under investigation. 
 
A.9.4 Serious adverse events (SAE) 
An adverse event or suspected adverse reaction is considered “serious” if, 
in the view of the investigator, it results in any of the following outcomes: 
• Death 
• A life-threatening event: An AE is considered “life-threatening” if, 
in the view of the investigator, its occurrence places the subject 
at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death. 
• Inpatient hospitalization or prolongation of existing 
hospitalization 
• Persistent or significant incapacity or substantial disruption of 
the ability to conduct normal life functions 
• Important medical events that may not result in death, be life 
threatening, or require hospitalization may be considered 





may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above. 
A.9.5 Causality or relatedness definition 
The relationship, or attribution, of an adverse event to the study drug will 
initially be determined by the investigator and recorded on the appropriate 
AE/SAE form. The relationship of an adverse event to study therapy regimen or 
procedures will be determined using the descriptors and definitions provided in 
Table A.3. 
 
A.9.6 Severity or intensity definition 
The severity of adverse events experienced by the study subjects is 
according to the criteria set forth in the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events Version (CTCAE). This document 
(referred to herein as the NCI-CTCAE manual) provides a common language to 
describe levels of severity, to analyze and interpret data, and to articulate the 
clinical significance of all adverse events.  
Adverse events will be graded on a scale from 1 to 5 according to the 
following standards in the NCI-CTCAE manual: 
Grade 1 = mild adverse event. 
Grade 2 = moderate adverse event. 
Grade 3 = severe and undesirable adverse event. 
Grade 4 = life-threatening or disabling adverse event. 





Adverse events will be collected from the time of the first protocol 
mandated procedure until the study completion, or until 30 days after the subject 
prematurely withdraws from the study. 
 
A.10 Collection and recording of adverse events 
A.10.1 Collection period 
Adverse events will be collected from the time of first protocol mandated 
procedure, until subject completes study participation or until 30 days after 
subject prematurely withdraws (without withdrawing consent) or is withdrawn 
from the study. 
 
A.10.2 Collecting adverse events 
Adverse events (including SAEs) may be discovered through any of these 
methods: 
• Observing the subject. 
• Questioning the subject in an objective manner. 
• Receiving an unsolicited complaint from the subject. 
• In addition, an abnormal value or result from a clinical or 
laboratory evaluation can also indicate an adverse event. 
 
A.10.3 Recording adverse events 
Throughout the study, the investigator will record adverse events and 





relationship to study therapy regimen or study procedure. All adverse events 
must be reported on the appropriate adverse events form within 5 business days 
of the learning of the adverse event(s). Once recorded, an AE/SAE will be 
followed until it resolves with or without sequelae, or until the end of study 
participation, or until 30 days after the subject prematurely withdraws or is 
withdrawn from the study, whichever occurs first. 
 
A.11 Reporting of serious adverse events 
A.11.1 Reporting of serious adverse events to sponsor 
Timely reporting of adverse events is required.  Investigators must report 
all serious adverse events, regardless of relationship or expectedness to the IRB 
an sponsor within 2 days of discovering the event. For serious adverse events, 
all requested information on the AE/SAE should be provided to the DSMB. 
However, unavailable details of the event should not delay submission of the 
known information. As additional details become available, the AE/SAE form 
should be updated and submitted. 
 
A.11.2 Final report 
A final study report will be provided to health authorities of all adverse 
events classified as: 
 Serious, expected, suspected adverse reactions  
 Serious and not a suspected adverse reaction  






Note that all adverse events (not just those requiring 2 day reporting) will be 
reported in the final report. 
 
A.11.3 Expedited reporting within 15 calendar days 
The sponsor must notify the appropriate health authorities and the 
investigators as soon as possible, or within 15 calendar days if the adverse event 
is classified as one of the following: 
 Serious and unexpected suspected adverse reaction.  Expedited 
reports are to include, in an aggregate analysis, specific events that 
occur more frequently in the investigational drug than in a 
concurrent or control group. 
 Any findings from other studies that suggest a significant risk in 
humans exposed to ASLAN002. This includes findings from animal 
or in vitro testing that suggest a significant risk in humans exposed 
to the drug. Ordinarily, such a finding would result in a safety-
related change in the protocol, informed consent, or other aspects 
of the overall conduct of the trial, will be reported. 
 
A.11.4 Expedited reporting within 7 calendar days 
The sponsor must notify the appropriate health authorities and the 
investigators as soon as possible, or within 7 calendar days, of any unexpected 






A.11.5 Reporting of adverse events to IRBs 
Investigator will report adverse events, including expedited reports, in a 
timely fashion to the local IRB in accordance with applicable regulations and 
guidelines.  
 
A.12 Data management 
A.12.1 Privacy protections   
A computer-generated list will be kept in password protected encrypted 
computer on site. A back up of the list will be kept on a separate password 
protected encrypted computer.  Only the randomization administrator will have 
access to this list. 
 
A.12.2 Confidentiality precautions 
  Participant identifiers will be stored separately from the coded, participant 
data.   All data that will be transferred or transported outside of the institution will 
be encrypted and stored on password protected encrypted computers.  There will 
be no photos, medical images, or recording (voice or video) obtained 
 
A.12.3 Collaborator communications 
  We will use eRoom™ to provide a “digital office” to support secure, 
conﬁdential communication and collaboration among study investigators. The 
software is Web–based and uses an office metaphor of rooms that may contain 





based application will provide researchers secure access to research data even if 
not inside the study area. All data stored on eRoom will be de-identified.  
 
A.12.4 Study site 
Huntsman Cancer Institute High Risk Breast Cancer Clinic will serve as 
the research site for the investigation. The High Risk Breast Cancer Clinic is 
under the direction of Dr. Saundra S. Buys.  
 
A.12.5 Network  
The Huntsman Cancer Institute coordinates its network infrastructure and 
security with the Health Sciences Campus (HSC) information systems at the 
University of Utah. This provides Huntsman Cancer Institute with effective ﬁrewall 
hardware, automatic network intrusion detection, and the expertise of dedicated 
security experts working at the University. Network equipment includes three 
high-speed switches and two hubs. User authentication is centralized with two 
Windows 2003 domain servers. Communication over public networks is 
encrypted with virtual point-to-point sessions using secure socket layer (SSL) or 
virtual private network (VPN) technologies, both of which provide at least 128 bit 
encryption. eRoom™ and other web applications use the SSL protocol to 
transmit data securely over the Internet. Direct access to Huntsman Cancer 
Institute machines is only available while physically located inside the Huntsman 





intrusion attempts, security scans are regularly run against our servers, and our 
IT staff is notified of intrusion alerts. 
  
A.13 Strengths and limitations of overall design 
A.13.1 Strengths 
This study is strengthened by the use of randomization, blinding, and use 
of a placebo comparator group. 
 
A.13.2 Limitations 
The study is short term and is not designed to address survival points 
(progression free survival). In addition, the short study follow-up and small 
sample size are not adequate to accurately reflect effect of the drug on skeletal 
events. It is likely that MSP expression can function as a biomarker for response 
to ASLAN002. If MSP expression is rare in breast cancer patients, using an 
unselected patient population may result in a lack of overall efficacy even if the 
drug was efficacious in the MSP expressing subpopulation. In addition, this is a 
single center investigation enrolling a very specific patient population, and our 
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Table A.2. Sample size estimates for a two-arm parallel group design with two-











Table A.3 Descriptions and definitions to determine causality of adverse events 
 
Detectable 
difference SD n per group total n 
20% 5% 3 6 
 10% 6 12 
 20% 22 44 
 30% 48 96 
  40% 85 170 
15% 5% 4 8 
 10% 10 20 
 20% 38 76 
 30% 85 170 
  40% 150 300 
10% 5% 6 12 
 10% 22 44 
 20% 85 170 
 30% 190 380 
  40% 337 674 
5% 5% 22 44 
 10% 85 170 
 20% 337 674 
 30% 758 1516 
  40% 1346 2692 








2 Possible The adverse event has a reasonable 
possibility to be related; there is 
evidence to suggest a causal 
relationship. 
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